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Abstract
The field of synthetic mRNA therapeutics is a rapidly expanding arm of gene
therapies. The use of mRNA provides multiple benefits over viral or DNA vectors.
synthetic mRNA vectors are immediately translated into protein after entering the
cytoplasm of cells in contrast to DNA vectors that must first be transcribed to mRNA in
the nucleus. This allows synthetic mRNA to produce a therapeutic protein in any cell
type, including non-dividing cells. In addition, the non-replicative nature of mRNA means
that insertional mutagenesis or generation of escape mutants is not a concern.
However, the stimulation of innate immune responses by unmodified synthetic mRNA
prevented widespread clinical applications.
The discovery that incorporation of modified nucleotides, such as pseudouridine
or 5-methylcytosine, prevents the recognition by innate immune sensors has renewed
interest in the use of synthetic mRNA as a therapeutic. In conjunction, numerous posttranscriptional regulatory elements have recently been described in mRNA. Adding
these regulatory elements to synthetic mRNA allows control of the expression of the
encoded protein in tissue-, cell-, or environmental-specific conditions. However, the
influence that the modified nucleotides commonly incorporated in synthetic mRNA have
on the regulatory capacity of these elements has not been examined.
In this study we investigated what effects modified nucleotides have on the
regulation of synthetic mRNA by microRNA (miRNA switch). We found that nucleotide

xiv

modifications that increase the translation of the synthetic mRNA tended to decrease
the regulatory capacity of microRNA switch. Inclusion of multiple microRNA target sites
at the 3’ UTR of the synthetic mRNA was able to minimize the loss of miRNAdependent regulation of the miRNA switch, but microRNA target sites complementary to
the six-nucleotide microRNA “seed” sequence were more affected to nucleotide
modification. We found the effect of nucleotide modifications varied between microRNA
species and was not determined by the proportion of modified nucleotides present in the
microRNA target sites. Finally, we observed that utilizing a single microRNA target site
at the 5’ UTR of the synthetic mRNA completely ameliorated the loss of regulation due
to nucleotide modifications.
Because synthetic mRNA are easy to produce and can be made to encode any
protein of interest, they are ideal for clinical development. Currently there are over 45
clinical trials underway utilizing synthetic mRNA as a monotherapy or in conjunction with
other therapeutics. Most of these clinical trials are focused on cancer immunotherapy,
particularly autologous T-cell therapy. This therapeutic modality is well suited for
synthetic mRNA as the target cells are transfected ex vivo. This avoids the major
obstacles that synthetic mRNA therapeutics must still overcome: delivery to target
organs.
The sensitivity of synthetic mRNA to extracellular ribonucleases requires
encapsulation of the mRNA in a protective nanoparticle. Numerous such nanoparticles
have been reported, but nearly all are variations on either lipid nanoparticles or
polymeric nanoparticles. The advances made thus far with these two mRNA delivery
platforms have significantly reduced their toxicity, however the endosomal escape rate

xv

of these particles remains well below 5%. Furthermore, when administered systemically
these nanoparticles are avidly taken up by sentinel macrophages of the liver and spleen
or hepatocytes. The accumulation of particles in the liver has thus far limited the
applications of mRNA therapeutics to diseases and disorders that are liver-specific or
that can be treated by using the liver as a biosynthetic depot. Expanding the clinical
application of synthetic mRNA may require the discovery of novel delivery platforms that
are capable of targeting other organs.
In this study we also tested the delivery of synthetic mRNA using a small cell
penetrating peptide, called p5RHH, that is derived from bee venom protein melittin. We
showed that in the presence of mRNA, p5RHH self-assembles into spherical
nanoparticles that display a high degree of RNase resistance. These nanoparticles were
consistently sized regardless of the length of the mRNA payload. Furthermore, after
uptake by cells, p5RHH-mRNA nanoparticles displayed a high degree of endosomal
escape that was dependent upon the acidification of endosomes, which disassembles
the nanoparticles. The high concentration of p5RHH in the lumen of the endosome led
to efficient endosomal disruption and produces minimal cytotoxic effects. When the
p5RHH-mRNA nanoparticles were injected intravenously into an atherosclerotic mouse,
we observed robust expression of the payload mRNA in only the atherosclerotic
plaques. The lack of expression in typical depot organs, such as the liver, spleen, lungs,
or kidneys, was also confirmed in a normal mouse. The simplicity and specificity of
p5RHH-mRNA nanoparticles makes them an ideal candidate for further pre-clinical
development as an mRNA delivery platform.
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Chapter 1
Eukaryotic mRNA Biogenesis and Function
mRNA Biogenesis
The expression of mRNA is the primary phenotypic determinant of a cell; the
epigenetic patterning of a cell’s DNA gives rise to a pool of mRNAs that are dynamically
regulated by their protein products in response to internal and external stimuli. The
production of eukaryotic mRNA is a highly regulated and concerted process, that
includes transcription from genomic DNA and processing of transcripts to form mature
mRNA.

Transcription of pre-mRNA
The production of mRNA begins with the transcription of precursor (pre)-mRNA
from DNA by RNA polymerase II. RNA polymerase II is recruited to the promoter region
of a gene by DNA-bound transcription factors. Because the recruitment of RNA
polymerase II to the promoter does not displace the transcription factors bound there,
multiple polymerases can transcribe the same gene simultaneously 1.
Once bound, the RNA polymerase II unwinds the double-stranded DNA and
begins to synthesize an RNA version of the coding strand of DNA based on WatsonCrick base pairing of free ribonucleotides with the complementary strand of DNA. The
pre-mRNA transcript is elongated as the polymerase continues along the gene.
Termination of transcription by RNA polymerase II is caused by recognition of the
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polyadenylation signal which leads to cleavage and release of the nascent pre-mRNA 2.
Importantly, RNA polymerase II contains an unstructured C-terminal domain that
regulates its activity and also localizes proteins necessary for processing the nascent
transcript 2.

Addition of the 5’ Cap
The first step of processing of pre-mRNA into mature mRNA is the addition of the
5’ cap. Capping of mRNA is essential in eukaryotes for avoidance of the innate immune
system and recognition of mRNA by conventional translation initiators. Though, under
stress conditions cap-independent translation can be used to express a specific subset
of the cellular mRNA pool 3. Capping begins after approximately 25 nucleotides have
been transcribed. The initial enzymatic step by RNA triphosphatase converts the 5’
triphosphate of the nascent pre-mRNA into a diphosphate. This allows RNA
guanyltransferase to attach a guanosine monophosphate to the 5’ of the pre-mRNA to
form a 5’-5’ triphosphate bond. The attached guanosine is then methylated at N7 to
produce the 7-methylguanosine (m7G) Cap0. In higher order eukaryotes, the Cap0 is
further modified by the addition of another methyl group to the 2’ hydroxyl of the ribose
sugar of the neighboring nucleotide to produce Cap1 4. Additional methylation of 2’
hydroxyl of the second transcribed nucleotide to form Cap2 occurs in about half of all
mRNAs, which unlike Cap1 can also occur in the cytoplasm after nuclear export of the
mature mRNA.
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Splicing of pre-mRNA
In eukaryotes, the coding portions of a gene may be interspersed with noncoding regions, called exons and introns respectively. Transcription of a gene includes
both of these regions. However, the intronic regions of a gene are rapidly spliced out of
the transcript by the spliceosome. The assembly and function of the human
spliceosome involves approximately 300 proteins and 5 small nuclear RNAs 5.
Assembly of the spliceosome requires identification of the 5’ splice site by the U1
snRNP and a branch point adenine by the U2 snRNP. After the spliceosome is
assembled, the hydroxyl group of the branch point adenine is used to perform a
nucleophilic attack and covalently link to a guanosine at the 5’ splice site forming a
intronic lariat. The exposed 3’ hydroxyl group of the upstream exon is then able to be
covalently linked to a guanosine in the 3’ splice site of the downstream exon, joining the
two exons. After splicing is completed a complex of eukaryotic initiation factor 4A3,
MAGOH, Y14 and metastatic lymph node 51 are deposited 24 nucleotides upstream of
the exon-exon junction. This Exon Junction Complex (EJC) aids in the export of mature
mRNA from the nucleus to the cytoplasm and plays a role in degradation of mRNA
transcripts with premature stop codons 6. The splicing of pre-mRNA transcripts can be
altered by cells to produce different isoforms of a gene. However, mutations can also
disrupt normal splicing of a gene to produce a deleterious isoform, such as is seen in
Duchenne Muscular Dystrophy 5.

3

3’ Polyadenylation
The final modification needed for production of eukaryotic mRNA is the addition
of a polyadenylate (poly(A)) tail. The addition of the poly(A) tail is intrinsically linked to
the termination of transcription by RNA polymerase II, which facilitates assembly of the
3’ processing complex via its C-terminal domain. The cleavage and polyadenylation
specificity factor (CPSF) protein complex recognizes the AAUAAA polyadenylation
sequence of the pre-mRNA transcript and recruits cleavage stimulation factor, cleavage
factor 1 and 2, poly(A) polymerase (PAP), and poly(A) binding protein (PAB2) 7. The
activity of the cleavage factors is inhibited in the absence of PAP, ensuring tight
coupling of pre-mRNA cleavage and polyadenylation 8. The site of cleavage is not the
same on each copy of a transcript. However, there is a strong preference for cleavage
after a CA dinucleotide 10 to 30 nucleotides downstream of the polyadenylation signal 9.
Mutation of the dinucleotide can significantly alter the efficiency of 3’ processing, as is
seen in the case of a mutation to a CA dinucleotide in the prothrombin gene that causes
hereditary thrombophilia due to more efficient production of prothrombin mRNA 10. The
length of the poly(A) tail is determined by the duration of PAP association with CPSF
and limits the number of added adenines to approximately 250, which is shortened in
the absence of PAB2 11. The binding of PAB2 along the poly(A) tail promotes nuclear
export and recruitment of translation initiation factors in the cytoplasm 12.

Post-transcriptional Regulation of mRNA
Once the mRNA has been transcribed the cell can still exert control over
translation of the encoded protein in a variety of ways. To prevent wasteful energy spent
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translating unwanted mRNA, cells exhibit a strong preference for regulating the initiation
of translation over other mechanisms, such as transcript degradation. Most of these
pathways involve the two untranslated regions (UTR) located at the 5’ and 3’ of the
coding sequence.

Role of the Untranslated Regions
The importance of UTRs is highlighted by the high degree of localized
evolutionary conserved regulatory elements 13,14. Furthermore, a large expansion in the
UTRs of genes is observed in higher order organisms, indicating that morphological
complexity is perhaps driven by regulatory patterning rather than an increase in protein
diversity 15,16.

5’ Untranslated Region
As mentioned above, under certain cellular stresses, such as hypoxia, there is a
switch away from cap-dependent translation. A subset of cellular mRNAs possess
internal ribosome entry sites (IRES), which allow for ribosome formation and translation
of the encoded protein under stress conditions 17. This strategy is also responsible for
transcription of cell cycle proteins like PITSLRE (p58), which is involved in mitotic
spindle formation at the G2/M checkpoint 18. In addition, IRES-mediated translation is a
key driver of protein expression in apoptotic cells as the cap-dependent translation
factors are cleaved by caspases, allowing cells to continue producing the proteins
necessary for the apoptotic process 19.
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Another mechanism for driving cap-independent translation has been observed
for a small subset of transcripts which were shown to bind eukaryotic initiation factor 3
(eIF3) to stem-loop structures in the 5’ UTR. Unlike IRES, these eIF3-binding sites
exhibited the ability to promote or inhibit translation of transcripts of c-Jun and B cell
translocation gene 1, respectively 20,21. Further studies showed that the binding of eIF3
to the 5’ UTR is mediated by the reversible nucleotide modification N6-methyladenosine
(m6A) and that a single m6A in the 5’ UTR was sufficient for eIF3 to bypass capdependent translation 22.
The secondary structure of the 5’ UTR can also affect the efficiency of
translation. The 5’ UTR tends to be less structured than the open reading frame, and
transcripts with highly structured 5’ UTRs produced less protein than transcripts with
unstructured 5’ UTRs 23. The helicase activity of eIF4A is required to unwind these
highly structured regions. However, the binding of recognition proteins to the secondary
structures in the 5’ UTR, such as iron response elements of ferritin and ferriportin, can
prevent cap-dependent translation machinery assembly and subsequent unwinding by
eIF4A. These recognition proteins are often responsive to environmental stimuli, such
as the availability of cytoplasmic iron, and dynamically control the translation of their
target transcripts 24.

3’ Untranslated Region and Poly(A) Tail
Nearly all eukaryotic mRNA is translated in pseudo-circular conformation due to
the interaction of the eIF4G subunit of the cap-binding complex with PAB2 on the
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poly(A) tail. Decreasing the distance between the cap-binding complex and the stop
codon may improve translation by increasing the rate of ribosome recycling 25.
While the function of 5’ UTR is primarily to regulate translation initiation, the 3’
UTR of eukaryotic mRNA has a more diverse set of functions. The 3’ UTR, like the 5’
UTR, is capable of regulating the initiation of translation. Indeed, some of the same
motifs discussed above, such as the iron response elements, can also exert their effects
on translation when present in the 3’ UTR 26. In addition, the hairpin structures
responsible for the alternative decoding of the “UGA” stop codon as selenocysteine are
present in the 3’ UTR of selenoproteins 27. However, the primary function of the 3’ UTR
is to provide binding sites for a variety of proteins that regulate mRNA turnover and
sequence-specific transcript silencing.

mRNA Stability and Turnover
The level a given protein in a cell is often correlated with the number of mRNA
transcripts that encode that protein 28. Transcript expression levels are determined by
the balance of transcription and degradation. Like transcription, mRNA turnover must be
a robust and tightly regulated process for cells to maintain mRNA expression levels at a
steady state and to alter production of encoded proteins as needed.

mRNA Degradation
mRNA transcripts are constantly attacked by cytoplasmic nucleases. The 5’ end
of mRNA transcripts are largely protected from exonuclease-mediated degradation by
the presence of the 5’ cap. However, there are multiple deadenylases, such as poly(A)
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ribonuclease, that specifically target the poly(A) tail by recognition of the 5’ cap, PAB2
or other RNA binding proteins. The removal of the poly(A) tail often serves as a trigger
for the rapid inactivation of the mRNA transcript by removal of the 5’ cap and associated
translational machinery via decapping protein 2 (DCP2) 29. The decapped mRNA is then
degraded from both the 5’ and 3’ ends by cytoplasmic exonucleases 28.
Degradation of mRNA may also be initiated by endonuclease attacks. Only five
such endonucleases have been identified, and the specificity of their activity is still
under investigation. However, the activation of endonuclease-mediated mRNA
degradation seems to be triggered in response to stimuli such as cellular or
endoplasmic reticulum stress 30. The products of endonucleolytic cleavage of mRNA are
further degraded by the same 5’ and 3’ exonucleases discussed above.

Determinants of mRNA Stability
The stability of mRNA is influenced by factors intrinsic to the transcript, such as
destabilizing AU-rich elements (ARE) and GU-rich elements (GRE), as wells extrinsic
regulatory agents, such as RNA binding proteins. In addition, the effects of these factors
may be linked to the translation, or lack thereof, of the mRNA transcript.
ARE and GRE are “AUUUA” and “UGUUUGUUUGU” sequences, respectively,
that occur in uridine enriched stretches of 3’ UTRs. These sequences are recognized by
ARE- or GRE-binding proteins, which typically induce rapid degradation of the bound
transcript via decapping 31,32. However, one ARE-binding protein family, ELAV-like
which is also known as human antigen, increases mRNA stability after binding to the
ARE. The dysregulation of ARE-binding proteins has clinical implications in cancer as
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there is significant enrichment of ARE in genes involved in cell cycle and proliferation,
many of which are classified as protooncogenes 33.
The translation status of an mRNA transcript has a profound impact on the its
stability. The principal determinant of mRNA stability was recently shown to be the
stochastic competition between the 5’ cap-binding translation initiation factors and
decapping enzymes 34. In addition, the efficiency of translation also affects the half-life
of mRNA transcripts. The composition of codons in the mRNA transcript and the relative
abundance of the cognate transfer RNA (tRNA) in the cell can limit the rate of
translation. The inclusion of rare codons in an mRNA transcript decreases protein
production and causes ribosomal stalling 35. This stalling can be sensed by RNA binding
proteins such as DEAD-box helicase 6 (DDX6) which promotes removal of the 5’ cap
and subsequent mRNA transcript degradation 36.

Silencing by microRNA
In addition to the post-transcriptional regulators discussed above, most
eukaryotes possess an RNA-directed transcript silencing system that identifies its
targets by Watson-Crick base pairing between a ~22 nucleotide single stranded RNA,
called a microRNA (miRNA), and a complementary target site on an mRNA. The activity
of miRNA provides an additional layer of dynamic control over mRNA translation and
stability. However, the primary physiological role of miRNA is to fine tune gene
expression. Many miRNA are expressed in specific types of cells, such as the
endothelial cell specific miR-126, while others are almost ubiquitously expressed like
miR-3960 37–39.
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microRNA Biogenesis
RNA polymerase II transcription of genes with short hairpin structures located in
intronic regions or independent non-coding genes, called primary microRNA (primiRNA), results in cleavage by nuclear Microprocessor complex 40. The Microprocessor
complex is made up the catalytic Drosha subunit and two structural DGCR8 subunits.
All three subunits function in the recognition of the stem-loop structure of the pri-miRNA.
Drosha recognizes the single stranded RNA (ssRNA)- double stranded RNA (dsRNA)
junction. The size of Drosha and the helical structure of the dsRNA ensures that primiRNA are cleaved 11 nt from the ssRNA-dsRNA junction and 22 nt from the apical
loop with a 2 nt overhang on the 3’ end to form the precursor-miRNA (pre-miRNA) 41.
The pre-miRNA is then exported from the nucleus after binding to Exportin 5 and
RAs-related Nuclear protein (RAN)-GTP 42. In the cytoplasm, pre-miRNA is further
processed by Dicer, which recognizes the 5’ end of the pre-mRNA. Again the helical
structure of the dsRNA allows Dicer to specifically cleave the both strands of the premiRNA 22 nt from each end to produce two mature miRNA 43.

The RNA-induced Silencing Complex
The mature miRNA remains double stranded until they are loaded into the RNAinduced Silencing Complex (RISC). The mechanisms and proteins involved in the
loading of miRNA duplexes into Argonaute (Ago) proteins, the effector subunit of the
RISC, is not well conserved between mammals and lower order organisms like
Drosophila. In Drosophila, Dicer-2 (dcr-2) and the dsRNA binding protein R2D2
coordinate the loading of the miRNA into Ago 44. However in humans and mice, Dicer is
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not needed for loading of the miRNA duplexes, although a Dicer-Ago2-TRBP (TARRNA binding protein) complex has been described 45,46. The bulkiness of the miRNA
duplex necessitates a energetically unfavorable conformational change in Ago that is
driven by adenosine triphosphate (ATP) hydrolysis by Heat shock protein 90 (Hsp90) in
all organisms 47.
Once the miRNA duplex is loaded in to Ago, one of the strands must be ejected
from the complex to allow for scanning of target mRNAs. Which strand of the miRNA
duplex remains bound in Ago depends primarily on the stability of the initial interaction
of the 5’ monophosphate nucleotide with the middle (MID) domain of Ago, which shows
a preference for binding adenine or uridine over guanosine or cytosine 48. Removal of
the unincorporated passenger strand is driven by pressure from the Ago PiwiArgonaute-Zwille (PAZ) domain that is displaced by loading of the miRNA duplex. In
human Ago2 is the only Ago protein that has the ability to endonucleolyticaly cleave
target RNAs, and cleavage of the passenger strand facilitates its release from the RISC
49

.

Mechanisms of microRNA Activity
Once the guide strand of miRNA has been loaded, the RISC begins scanning
cytoplasmic transcripts including mRNA for target sites that are complementary to the
loaded miRNA. Recognition is mediated by nucleotides 2 – 8 of the guide miRNA, called
the seed sequence 50. This seed sequence may be conserved in multiple miRNA,
forming a miRNA family. Over half of the human transcriptome is targeted by miRNA,

11

and each miRNA or miRNA family can targets hundreds of different mRNA transcripts
51

.
In their canonical role, miRNA repress the expression of targeted mRNA. This

repression can be accomplished by two different mechanisms. When the RISC binds to
a miRNA target site that is complementary to only the seed sequence, which is the
predominant type of target site in animals, the primary means for miRNA-mediated
silencing is the recruitment of mRNA degradation machinery. Ago proteins that are
loaded with a miRNA can form stable complexes with the trinucleotide repeat containing
protein 6 (TRN6) 52. After binding to the cognate miRNA target site, the Ago-TRN6
complex interacts with poly(A) binding proteins to recruit deadenylases and the carbon
catabolite repressor 4-Negative on TATA complex (CCR4-NOT). CCR4-NOT in turn
recruits the DDX6 decapping enzyme 53. In addition, DDX6 competes with translation
initiators to reduce protein expression prior to decapping.
In contrast to the translational repression mediated by the RISC binding to the
seed complementary sequence, binding to target sites with extensive or perfect
complementarity to the entire miRNA induces cleavage by Ago proteins. In humans,
Ago2 is the only Ago protein that has RNA cleaving activity, and thus far only 20
endogenous mRNA transcripts have been experimentally proven to be cleaved by Ago
in all mammals. However, the cleavage of mRNA by the RISC is the predominant
mechanism of action in plants 50. Importantly, this mechanism has been extensively
exploited in the design of short interfering RNA (siRNA). Extensive or perfect
complementarity positions the substrate mRNA within the catalytic PIWI domain of
Ago2, which cleaves the phosphodiester backbone between the nucleotides
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complementary to nucleotides 10-11 of the loaded miRNA 54. Once the mRNA is
cleaved and degraded the miRNA-loaded RISC is freed to search for additional targets.

Translation of mRNA to Protein
mRNA serves as the intermediate step between the storage of gene in the DNA and the
effector of the gene, protein. Like transcription, translation is a tightly controlled process,
and the translation of an mRNA sequence to a peptide sequence is the final regulatory
checkpoint at which a cell can regulate mRNA. Translation in eukaryotes is highly
coordinated and requires specific factors for translation initiation, peptide elongation,
and termination. Translation also serves as a key quality control checkpoint for
detecting and disposing of aberrant mRNAs.

Initiation of Translation
As discussed above, the initiation of translation plays a major role in the stability
of an mRNA transcript. The synthesis of proteins requires a large energy investment by
a cell. Halting the initiation of translation is the most effective way of preventing this loss
of energy during times of cellular stress or nutrient deprivation. It is not surprising
therefore that cells tightly regulate the drivers of translation initiation.

Eukaryotic Translation Initiation Factors
The primary method of translation initiation in eukaryotes is dependent on the 5’
cap of the substrate mRNA. Cap-dependent translation initiation requires the
independent preassembly of eukaryotic initiation factors (eIF) on the substrate mRNA,
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the 40S ribosomal subunit, and methionine transfer RNA (tRNAiMet). The 5’ cap is
recognized by the eIF4F complex, composed of the IF4A, eIF4G, and eIF4E subunits.
Once bound, eIF4F hydrolyzes ATP to unwind a small stretch of the 5’ UTR. This
“activated” mRNA is prepared for loading into the pre-initiation complex and subsequent
translation.
The pre-initiation complex is formed by the binding of eIF3 and eIF1A to the 40S
ribosomal subunit. The complex is then charged by the binding of the guanosine
triphosphate (GTP)-eIF2-tRNAiMet ternary complex at the ribosomal peptidyl site (P-site)
55

. The charged pre-initiation complex, also known as the 43S ribosomal subunit, then

associates with the activated mRNA via interactions between eIF3 and eIF4G.
Translation initiation is regulated by inactivation eIF4E or eIF2. eIF4E is the
target of three eIF4E-binding proteins (4E-BP) that are regulated by environmental
signals, such as growth factors, as well as stressors like nutrient deprivation. The
reversible binding of 4E-BP prevents eIF4E binding to eIF4G to form the eIF4F
complex. Phosphorylation of 4E-BP in response to growth factors releases the bound
eIF4E and allows for translation initiation 56. This phosphorylation is carried out by the
FKBP12-rapamycin associated protein/mammalian target of rapamycin (FRAP/mTOR),
which is a primary sensor of nutrient availability and integrates initiation of translation
with a variety of other cellular processes 57.
Unlike the singular kinase regulating eIF4E, there are four known regulatory
kinases that target mammalian eIF2. Three of these sensors, general control
nonderepressible 2 (GCN2), hemin-regulated inhibitor kinase (HRI), and PKR-like ER
kinase (PERK), detect states of cellular stress or nutrient deprivation 58. The fourth
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sensor, double-stranded RNA-activated protein kinase (PKR), is primarily activated in
response to viral infection but can also be activated by synthetic mRNA 59.
Phosphorylation of eIF2 sequesters eIF2B, which prevents recycling of GDP-eIF2 to the
active GTP-eIF2 and subsequent formation of the ternary complex.

Ribosome Assembly
After binding to the mRNA, the pre-initiation complex begins to move along the
mRNA in the 3’ direction. This movement is aided by the ATP-dependent helicase
activity of eIF4A 60. The complex continues to scan along the mRNA until it encounters
an “AUG” start codon that is recognized by the tRNAiMet anti-codon loop in the P-site of
the small ribosomal subunit. Recognition of the start codon triggers removal of the
bound initiation factors and ribosome assembly.
The joining of the large ribosomal subunit to the mRNA-bound small ribosomal
subunit requires another translation initiation factor, eIF5. The presence of eIF5
promotes the self-hydrolysis of GTP-eIF2 to GDP-eIF2, and the liberated phosphate ion
induces a conformational change in eIF5 that arrests the smaller ribosomal subunit on
the start codon. The recognition of the start codon also induces a conformational
change that releases eIF1 from the small ribosomal subunit, allowing for the large
ribosomal subunit to associate with the small ribosomal subunit. Formation of the
complete ribosome prompts hydrolysis of GTP on eIF5 that reduces its affinity for the
ribosome 61.
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Peptide Elongation
The assembled ribosome is now poised to translate the rest of the mRNA. The
continued translation decodes the mRNA into a peptide sequence and is coordinated by
a family of eukaryotic elongation factors (eEF). The rate of translation also plays a role
in the efficiency of protein production, balancing speed of synthesis with the time
required to properly fold the protein products. All of these processes are monitored by
the cell to prevent translation of degraded or degenerate mRNAs through No-Go Decay.

Decoding of mRNA
Translation proceeds one trinucleotide codon at a time, and each codon is
recognized by a single species of tRNA that possesses the complimentary anti-codon.
The amino acid loaded-tRNAs (aa-tRNA) are directed to the aminoacyl site (A-site) of
the ribosome as a complex with eEF1A and GTP. Loading of the complementary aatRNA induces a conformational change in eEF1A that induces hydrolysis of the GTP to
GDP and subsequent dissociation from the aa-tRNA. A peptide bond is rapidly formed
between the last amino acid in the peptide chain and the amino acid on the aa-tRNA,
forming a peptidyl-tRNA. The now uncharged tRNA in the P-site and peptidyl-tRNA in
the A-site induce a GTP-dependent translocation of the mRNA within the ribosome to
reposition the tRNAs in the exit site (E-site) and P-site, respectively. The hydrolysis of
GTP that drives translocation is carried out by eEF2, which is dissociated from the
ribosome by the resulting conformational change 62.
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Effects of Translation Rate
The rate at which the translation of mRNA occurs is largely determined by the
codon composition of the transcript. Optimal codons that are recognized by relatively
abundant tRNAs are translated at a higher rate than rare codons with less abundant
tRNAs. The inclusion of rare codons can induce a stall in translation and reduce the
amount of protein produced from an mRNA 35. However, both optimal and rare codons
are found to be evolutionarily conserved, indicating a need for ribosomal pausing.
Indeed, structured regions of proteins, such as a-helices, often exhibit a pattern of
optimal and rare codons that aids in the co-translational folding, while less structured
regions tend to be enriched in optimal codons 63.

No-Go Decay
While some ribosomal pausing is important to proper protein folding, excessive
pausing may be indicative of degraded or degenerate mRNA. Removing these mRNAs
and liberating the bound ribosomes is achieved by a mRNA surveillance pathway called
No-Go Decay. Details of the mechanism that induces this system are not currently well
understood, however, Dom34 and Hbs1 proteins have been shown to be involved in
No-Go Decay in yeast 64. Degradation of the mRNA transcript is driven by cleavage
within the mRNA exit tunnel of the ribosome and requires at least three stalled
ribosomes 65.
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Translation Termination
Proper translation of the mRNA requires that decoding terminates at the final
codon. This process, like initiation and elongation is regulated by a small set of proteins
called eukaryotic releases factors (eRFs). The activity of the eRFs is tied to recognition
of the final codon in the coding region of the mRNA, triggers the release of nascent
peptide to prevent production of truncated proteins, and disassembles the ribosome.
However, cells must also be able to detect when errors in translation termination occur
and destroy the defective mRNA.

Stop Codons
Like the initiation of translation, the site of translation termination is also encoded
within the mRNA as Stop codons. Unlike the Start codon, there are three codons that
signal for translation to stop: Amber (UAG), Ochre (UAA), and Opal (UGA). In humans
and other higher order eukaryotes, UGA is the most commonly used stop codon 66.
However, in highly expressed genes UAA is more frequently used, possibly due to the
higher efficiency of termination than UAG or UGA 67,68.
In a small set of proteins, UGA encodes for a selenocysteine rather than Stop.
This alternative decoding is mediated by a nearby selenocysteine incorporation
sequence 69. Expression of selenoproteins can be regulated by the abundance of
selenocysteine-tRNA; the lack of environmental selenium causes the UGA to be
decoded as Stop and prematurely terminates translation 70.
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Eukaryotic Release Factors
Recognition of all three stop codons in eukaryotes is mediated by eRF1, which
contains a codon recognition region similar in structure to the anticodon loop of tRNA 71.
Before entry into the ribosome, eRF1 forms a complex with eRF3 and GTP. Like tRNA,
eRF1 binds to the stop codon in the A-site of the ribosome, which induces hydrolysis of
the complexed GTP via eRF3 and positions the Gly-Gly-Gln motif of eRF1 to catalyze
the release of the nascent peptide from the peptidyl-tRNA in the P-site of the ribosome
72

. The eRF1/eRF3 complex can then promote disassembly of the large ribosomal

subunit, a process that is greatly accelerated by association with ATP Binding Cassette
Subfamily E Member 1 (ABCE1) 73. The small ribosomal subunit remains bound to the
mRNA until the deacetylated tRNA is removed by eIF1, which also initiates the
reformation of the preinitiation complex 74.

Nonsense-Mediated Decay
Mutations that create a stop codon from a sense codon are called nonsense
mutations. The inclusion of a premature stop codon in an mRNA can cause the
production of a truncated and potentially deleterious protein product. Cells possess an
mRNA quality control system that targets transcripts that are not completely translated
for degradation. In mammals this nonsense-mediated decay pathway relies on the exon
junction complexes (EJC) deposited on the mRNA during splicing. The EJC is normally
displaced during translation by ribosomes, but premature termination codons at least 50
nt upstream of the last exon junction will allow the EJC to persist on the mRNA
transcript 75. The remaining EJC is recognized by complex of suppressor with
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morphological effect on genitalia 1 (SMG1), Regulator of nonsense mediated decay 1
(UPF1), eRF1, and eRF3 (SURF). Binding of SURF to the EJC recruits UPF2 and
UPF3b and triggers dissociation eRF1 and eRF3 along with activation of the helicase
activity of UPF1. UPF1 proceeds along the transcript removing mRNA-binding proteins
to enable endonucleolytic attack by SMG6 76. The cleaved mRNA is then rapidly
degraded by mRNA decay due to decapping enzymes and deadenylases that are
recruited by the activated UPF1, UPF2, and UPF3b 77.

Nonstop-Mediated Decay
In addition to the premature translation termination of mRNAs with nonsense
mutations, cells must be able to recognize transcripts that fail to terminate translation
due to destruction of the stop codon by a nonstop mutation or premature
polyadenylation. Nonstop mutations can lead to accumulation of ribosomes on the
defective mRNA as eRF1 is not able to induce ribosomal release. In addition, the stalled
ribosomes increase the transcript’s resistance to 3’ to 5’ exonuclease degradation. In
mammals the stalled ribosomes are recognized by a complex of HBS1-like translation
GTPase (HBS1L; Hbs1) and pelota mRNA surveillance and ribosome rescue factor
(PELO; Dom34), which is also involved in No-Go decay discussed above. The Hbs1Dom34 complex interacts with the vacant A-site of the ribosome in a codon-independent
manner. Once bound to the ribosome, the Hbs1-Dom34 complex recruits mRNA
degradation machinery. Unlike normal mRNA degradation, Nonstop decay does not
induce deadenylation of the transcript and instead promotes attack by endonucleases
78

.
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Chapter 2
Design and Synthesis of Synthetic mRNA for Therapeutic Applications
Nucleic Acid Therapies
Replacing a defective, pathogenic gene using exogenous nucleic acids has the
potential to provide a curative treatment for many human diseases. The promise of
these gene therapies has driven research on the design and delivery of these
treatments for over 50 years. However, the applications of nucleic acid therapies extend
beyond correction of disease-causing mutations by gene therapy.

Overview of Nucleic Acid Therapies
The ability to deliver a specific gene to a cell enables manipulation of the cell’s
activity, metabolism, and even phenotype. Much of the research on nucleic acid
therapies has focused on the delivery of DNA to the target cells in the form of plasmids
or viral vectors. This work has produced multiple successes, including a treatment for
hereditary blindness 79 and the development of chimeric antigen receptor T-cell (CAR-T)
therapy for lymphomas and leukemia 80. However, the delivery of DNA to cells is not
without limitations and dangers.
Because the delivered DNA must be transcribed to produce the therapeutic
effect, it must bypass both the cellular and nuclear membranes. The breakdown of the
nuclear membrane during mitosis allows cytoplasmic DNA to be incorporated within the
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nuclei of the daughter cells. However, this largely precludes the use of DNA-based
therapeutics in non-dividing cells except when delivered using a lentiviral vector 81.
The use of retroviral vectors also allows for permanent integration of the
transgene into the genome of a cell. However, many retroviruses integrate randomly
into the host DNA and have to potential to disrupt normal gene expression. The danger
of insertional mutagenesis was highlighted after two patients treated with a retroviral
therapy for X-linked severe combined immunodeficiency developed leukemia 82,83. The
shift toward Adeno-associated virus (AAV) vectors in recent years has been driven in
part by the selective integration of AAV transgenes at a specific locus on chromosome
19 84.

Advantages of mRNA Therapeutics
Synthetic mRNA has recently begun to gain favor over DNA or viral vectors for
transient applications and therapies. The rise of mRNA therapeutics can be attributed to
the intrinsic advantages they hold over DNA vectors therapies. Unlike DNA vectors,
synthetic mRNAs can produce the encoded protein in any cell type, even non-dividing
cells, because synthetic mRNAs are immediately translated in the cytoplasm and do not
require translocation to the nucleus. Synthetic mRNA vectors carry no risk of insertional
mutagenesis or recombination. Furthermore, the production of synthetic mRNA is
carried out in a cell-free system that minimizes the potential for contamination, is much
simpler, cheaper and faster than the production of viral vectors, and can be quality
controlled to ensure uniformity and purity by high performance liquid chromatograph
(HPLC) 85.
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Innate Immune Response to Exogenous RNA
The viability of synthetic mRNA as a therapeutic has long been hindered by the
induction of the innate immune response. Barrier cells, such as vascular endothelial
cells, and immune sentinel cells, like dendritic cells, express membrane bound Toll-like
receptors (TLRs) that act as pattern recognition receptors (PRRs) for a variety of
ligands, including extracellular and endocytosed RNA. In addition, nearly every type of
mammalian cell possesses cytosolic PRRs capable of detecting viral RNA or synthetic
RNA. Activation of these various PRRs enable cells to initiate a variety of antiviral
responses 86.

Toll-like Receptors
The first PRRs that encounter exogenous RNA are the endosomal TLR3, TLR7,
and TLR8. The activation of these TLRs leads to the establishment of an antiviral
cellular state, by inducing the expression of various cytokines that produce a localized
inflammatory response and stall translation 87. TLR7 and TLR8 are both capable of
sensing ssRNA that is guanosine- or uridine-enriched 88. TLR7/8 is bound by a
cytosolic adapter protein, myeloid differentiation primary response 88 (MYD88), and
stimulation of TLR7/8 leads to activation of IL-1 receptor-associated kinase (IRAK)
family. IRAK phosphorylates TNF receptor associated factor 6 (TRAF6), which in turn
activates the IκB kinase (IKK) complex via transforming growth factor beta-activated
kinase 1 (TAK1). IKK subsequently activates nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) by ubiquitination of inhibitor κB (IκB) 89. NF-κB then
translocates to the nucleus and activates the transcription of pro-inflammatory cytokines
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such as tumor necrosis factor alpha (TNFa), interleukin 12 (IL-12), and interleukin 6 (IL6). In addition to activation of the TNFa pathway, MYD88 allows IRAK1 to
phosphorylate Interferon Regulatory Factor 7 (IRF7). IRF7 then induces expression of
interferon alpha (IFNa), which promotes expression of genes involved in anti-viral
defense in an autocrine and paracrine manner 90.
In contrast to TLR7/8, TLR3 recognizes dsRNA. TLR3 utilizes a different
cytoplasmic adapter, TIR-domain-containing adapter-inducing interferon-β (IFNb) (TRIF)
90

. Stimulation of TLR3 allows TRIF to bind and activate TRAF6, resulting in the nuclear

translocation of NF-κB. However, TRIF also mediates the phosphorylation of IRF3 via
TANK binding kinase 1 (TBK1) 89. Phosphorylated IRF3 induces expression of IFNb,
which induces the same antiviral response as INFa.

Cytosolic dsRNA Sensors
Unlike the TLRs that are found in barrier cells and immune sentinel cells, the
expression of cytosolic sensors is nearly ubiquitous. The cytosolic sensors induce 3
distinct responses upon stimulation: induction of an antiviral state, translational
inhibition, and ribonuclease (RNase)-mediated apoptosis (Figure 2.1). To control the
latter two responses, their activation is potentiated by interferon signaling.
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Figure 2.1. The components of the RNA-sensing innate immune response
Diagram of the various pattern-recognition receptors and the downstream signaling
cascade (blue) involved in the detection of RNA. Stimulation of the innate immune
response by RNA produces three primary effects (dark grey): inhibition of protein
translation, induction of an antiviral state, and RNase-mediated apoptosis.
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Production of interferons is mediated by two homologous cytosolic sensors of
dsRNA, retinoic acid inducible gene-I (RIG-I) and melanoma differentiation associated
gene 5 (MDA5), which belong to the RIG-I-like receptor family. RIG-I is most strongly
stimulated by short (<300 bp) dsRNA with a 5’ triphosphate, a feature common in viral
genomes that lack the 5’ cap 91. The ligands for MDA5, however, are not well
established, though it is known to be stimulated by long stretches (>2 kb) of poly(I:C)
dsRNA and mRNA lacking ribose 2’-O-methylation 92. Recent work has also
demonstrated that MDA5 is stimulated by mitochondrial dsRNA, which might escape
into the cytoplasm during viral infections 93. Signal transduction from both RIG-I and
MDA5 is carried out by an adaptor protein, mitochondrial antiviral signaling (MAVS).
MAVS functions much like the TLR3 adapter TRIF; activation of MAVS induces the
expression of INFa via TRAF6 and NF-κB translocation via the IKK complex 94.
PKR is another cytosolic dsRNA sensor. PKR is robustly expressed in all cell
types, but its expression is strongly induced by type 1 interferon (IFN⍺/IFNβ). Upon
dsRNA binding PKR dimerizes, autophosphorylates, and inhibits translation initiation by
phosphorylating eIF2α and prevents charging of the small ribosomal subunit with
tRNAiMet 95.
The final cytosolic sensor of dsRNA is the oligoadenylate synthetase family
(OAS), which is composed of three catalytically active members (OAS1, OAS2, and
OAS3) in humans. Activation of OAS1 can be triggered by short dsRNA structures as
short as 17 bp in length, while OAS2 requires dsRNA at least 35 bp in length for robust
activation 96,97. The size specificity of the ligand dsRNA is likely determined by the
presence of 1, 2, or 3 copies of the OAS homology domain in OAS1, OAS2, or OAS3,
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respectively 98. dsRNA binding induces a conformational change that exposes the
catalytic residues of OAS and allows for the production of 2’,5’-oligoadenylate second
messengers. The length of the 2’,5’-oligoadneylates varies among OAS1, OAS2, and
OAS3, but all three are capable of producing the trimers needed to activate the 2'-5'
oligoadenylate synthetase-dependent ribonuclease RNase (RNAse L) 99, which
endonucleolytically cleaves ssRNA in uridine-rich regions to produce 5’ hydroxyl and 3’
phosphate products that can be recognized by RIG-I and further induce or prolong
interferon expression 100. RNase L also specifically cleaves the 18S ribosomal RNA and
induces caspase-dependent apoptosis due to release of mitochondrial cytochrome C
101

.

Incorporation of Chemically Modified Nucleotides
Given the preponderance of secondary structure present in mRNA, cells must
possess a means of preventing activation of the innate immune response by their own
mRNA. The processing of pre-mRNA to mRNA places several identifying marks upon
cellular mRNA, such as the 5’ cap, and provides an opportunity for mRNA binding
proteins to attach before export to the cytoplasm. While synthetic mRNA is commonly
capped, robust activation of the innate immune response is still seen. Recently,
incorporation of various chemically-modified nucleotides (Figure 2.2) during in vitro
transcription has been shown to improve protein production and reduce immunogenicity
of synthetic mRNA. These modified nucleotides are also found in cellular mRNA, but
their abundance compared to unmodified nucleotides is extremely low, typically less
than 1%.
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Figure 2.2. Chemical structure of modified nucleotides commonly incorporated in
synthetic mRNA.
Representative unmodified and chemically-modified nucleotides produced by posttranscriptional modification of eukaryotic mRNA. Inclusion of these modified nucleotides
during in vitro transcription allows for direct incorporation into synthetic mRNA in
stoichiometrically controlled ratios.

28

Avoidance of Innate Immune Response
The endosomal TLRs are the first innate immune sensors encountered by
synthetic mRNA. Initial screening showed that a variety of nucleotide modifications,
including 6-methyladenosine (m6A), 5-methylcytosine (m5C), 2-thiouridine (s2U), and
pseudouridine (Ψ), could prevent recognition by TLRs 102. Recent work has also shown
that N1-methylpseudouridine (m1Ψ) modification prevents activation of TLR3 103.
Moreover, incorporation of Ψ, m5C, or m1Ψ also increased the expression of proteins
encoded by the synthetic mRNA 104. This increase in translation is due, at least in part,
to the decreased recognition of the modified mRNA by PKR 105,106. Interestingly, s2U
also prevented phosphorylation of eIF2⍺ by PKR, however the protein production was
decreased compared to unmodified mRNA. m6A modification did not increase the
production of protein and also failed to prevent PKR activation 104,105.
In cells lacking TLRs, RIG-I is the primary innate immune sensor for inducing
interferon expression in response to exogenous mRNA as the Cap1 structure prevents
activation of MDA5 92. Although Ψ-modified mRNA is recognized by RIG-I, it prevents
RIG-I activation by inhibiting the conformational change necessary for RIG-I to bind to
MAVS and induce of expression of INFβ 104,107.
Unmodified synthetic mRNA also induce severe cytotoxicity in some cell types,
likely due to the production of second messenger 2’,5’-oligoadenylates from OAS1 and
activation of RNase L. However, incorporation of Ψ, m6A, or s2U modifications in
mRNA prevented the activation of OAS1. Furthermore, Ψ-modified mRNA is more
resistant to cleavage by activated RNase L in vitro 108.

29

Changes in RNA Secondary Structure
Since the sensors of the innate immune system do not recognize specific
nucleotide sequences, but rather mRNA secondary structure, the ability of nucleotide
modifications to avoid detection must be mediated by changes in the mRNA structure.
In fact, addition of methyl group in m6A has been shown to greatly increase the energy
needed for m6A·U Watson-Crick base pairing compared to A·U and disrupts dsRNA
structures 109. This destabilization is supported by the enrichment of m6A nucleotides in
regions of dsRNA to ssRNA transition 110. Incorporation of Ψ promotes base stacking of
nearby nucleotides into A-form RNA, a compacted right-handed double-helix. The
compacting is due to stabilization by the N1 interacting with the ribose backbone 111.
s2U modification also increase bases stacking by making the C3’-endo conformation of
the ribose sugar more energetically favorable, thereby reducing the distance between
adjacent bases 112. Like Ψ and s2U, m5C is also thought to increase base stacking, but
the denser stacking is driven by increased hydrophobicity rather than direct stabilization
of backbone conformation 113.

Alternative Decoding of Modified Codons
In addition to altering the secondary structure of the mRNA transcript, the
inclusion of modified nucleotides can also alter the Watson-Crick base pairing energies.
m6A is known to decrease the energetic favorability of all potential base pairings, and
formation of m6A·U base pairs induces electrostatic tension due to steric clashing
between the 6’-methyl group and N7 of the m6A 110. s2U increases the specificity of
base pairing by stabilizing pairing with adenosine (s2U·A) and destabilizes pairing with
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guanine (s2U·G). Formal studies examining the effect of the reduced wobble base
pairing potential of s2U·G have not been performed, but s2U is commonly included in
anti-sense RNA oligos and siRNA to reduce off-target binding 114. In contrast, Ψ exhibits
significantly altered base pairing characteristics from unmodified uridine. Inclusion of Ψ
in a Stop codon (ΨAA, ΨAG, or ΨGA) almost completely prevented transcription
termination. Alternative decoding of this Nonstop codon varied depending on the codon
sequence; ΨAA encoded serine or threonine equally, ΨAG primarily encoded serine,
and ΨGA largely decoded to tyrosine 115. Whether Ψ induces alternative decoding of
sense codons has not yet been determined, but the functionality of proteins produced
by Ψ-modified synthetic mRNAs implies that any differences may be minimal 116,117.
Currently, m5C produces no known alterations in base pairing stability or decoding of
m5C-containing codons.

Codon Optimization
Synonymous codons encode for the same amino acid but differ in their sequence
on the mRNA transcript. As such, they are recognized by different species of tRNA. The
relative level of each tRNA in a cell varies by species and in response to metabolic
activity and cellular stress. The importance of the relationship between codon frequency
and tRNA abundance has produced several different measurements of codon usage
bias.
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Codon Usage Bias Indices
The first attempt at measuring codon optimality was based on the relative
abundance of tRNA species. The use of cognate codons for the most abundant tRNA
for each amino acid, the optimal codon, was found to correlate well with the protein
levels of the gene in Escherichia coli 118. The most common measurement of codon
usage bias is the codon adaptation index (CAI), which is the geometric mean of the ratio
of synonymous codons in given gene compared to usage of that codon in a set of highly
expressed genes. CAI values range from 0 to 1, and genes with a CAI near 1 are
predicted to be highly expressed 119. A measurement of codon usage bias that relies on
the expected codon frequency determined by the nucleotide composition of the
measured gene has also been shown to capture the effect of codon optimality on
protein abundance in E. coli without the need for a set of reference genes 120.
Therefore, engineering the sequence of synthetic mRNA to include a higher proportion
of optimal codons may provide an additional opportunity for increasing the expression of
the encoded protein.

Sequence Engineering for Protein Production
The degeneracy of the genetic code allows for an exceedingly large number of
mRNA transcripts to produce identical proteins. Editing of synthetic mRNA or other
gene vectors to contain a higher proportion of optimal codons can significantly increase
the production of the encoded protein 121,122. However, the generality of these results for
expression in humans and other higher order metazoans requires further study as most
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studies utilized bacterial or yeast models. In addition, codon usage bias in higher order
eukaryotes is markedly smaller than in bacteria and yeast 123.
Codon optimization algorithms vary in the degree of codon replacement, ranging
from complete replacement of all instances of an amino acid to adjustment of codon
usage to the endogenous rate. Some programs also seek to conserve regions with a
high proportion of rare codons as the reduced translation rate in these regions may be
required for proper protein folding or modification 124. In addition, preserving rare
codons in the beginning of the coding sequence has been shown to increase translation
of proteins 125. Further studies, especially ones that utilize synthetic mRNA, are required
to determine the true optimal codon usage.
Perhaps the clearest example of the functional effects of codon usage on
expression is the switch in E. coli tRNA charging upon amino acid starvation. The
preferential acylation of tRNAs that recognize rare codons enables efficient translation
of mRNAs enriched with those codons, such as genes involved in amino acid synthesis
126

. Importantly, a similar investigation using human cell lines found that genes involved

in protein recycling are enriched with rare codons that enable preferential translation
during amino acid starvation 127.
A similar change in the tRNA pool has also been found to drive preferential
translation of proliferation-associated genes or differentiation-associated genes in
normal and cancerous human cell lines. In particular, the abundance of tRNAiMet was
increased in proliferating cells 128. This phenomenon is supported by a study that
demonstrated an increase in human epithelial cell proliferation after overexpression of
tRNAiMet 129. Perturbations of tRNA gene expression have also been shown to drive
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metastasis in human cancer models 130. Therefore, it may be necessary to balance the
codon optimality of a synthetic mRNA to ensure efficient translation without disrupting
the availability of tRNA in a cell.

Structural Components for Transcript Optimization
As previously discussed, the maturation of eukaryotic pre-mRNA to mRNA
involves extensive processing and modification. The translation machinery of eukaryotic
cells built specifically to recognize the processed mRNA and target unprocessed or
malformed mRNA for degradation. Therefore, incorporation of these elements, such as
the 5’ cap and UTRs, into synthetic mRNA is required for an effective gene vector. The
flexibility and in vitro synthesis of synthetic mRNA provides a unique opportunity to
explore different methods of including the desired structural components and study the
effects of these components on the regulation of transcript stability and translation.

5’ Cap
The addition of the 5’ cap to synthetic mRNA is necessary for assembly of the
canonical translation initiation complex. However, the simplified transcription machinery
used for making synthetic mRNA does not enable co-transcriptional capping. The
enzymatic addition of the 5’ cap can be carried out after completion of the in vitro
transcription reaction. In eukaryotes, 5’ capping is carried out by multiple enzymes that
dephosphorylate the 5’ triphosphate, add a guanine nucleotide, and methylate the
added guanine. However, virus have evolved capping enzymes that combine some or
all of the requisite activity into a single protein 131. Many commercially available in vitro
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capping systems utilize a capping enzyme derived from Vaccinia virus that is capable of
generating Cap0 but lacks methyltransferase activity. Cap0 is then converted into Cap1
by an included 2’-O-methyltransferase (Figure 2.3 A). The enzymatic capping method
ensures that virtually all of the transcripts receive the 5’ Cap1.
The discovery of m7G cap analogs has allowed for co-transcriptional capping of
synthetic mRNA 86. The use of analogs simplifies the mRNA synthesis process but does
not guarantee the capping of every transcript. During IVT, regular guanine can be
incorporated in place of the cap analog, producing 80% capped mRNA when used at a
ratio of 4 m7GpppG to 1 guanine. The efficiency of the basic Cap0 analog m7GpppG
(Figure 2.3 B) is further reduced by half due incorporation in the reverse orientation,
with the m7G in the second nucleotide position. The design of cap analogs with 3’-Omethylation of the m7G was found to prevent incorporation in the reverse direction due
to the inability of RNA polymerase to attach the next nucleotide to the 3’ hydroxyl
(Figure 2.3 C). This Anti-Reverse Cap Analogs (ARCA) enables all of the capped
transcripts to be translated, but capping efficiency is still driven by stoichiometric
competition with guanine 132. Further modification of ARCA has produced new analogs
capable of increasing translation initiation, transcript stability, and biotin-labeling of
mRNA 133–135. However, all of the ARCA require subsequent methylation to produce
Cap1 structures. The recent development of Cap1 and Cap2 analogs may enable to
production of synthetic mRNA in a single reaction, but these analogs require a specific
AG or GG dinucleotide initiator sequences for efficient incorporation 136.
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Untranslated Regions
As previously discussed, the 5’ and 3’ UTR of mRNA transcripts play a key role in the
regulation and stability of the mRNA. Because the coding region of synthetic mRNA is
all that is necessary for the production of the desired protein, the flanking UTRs can be
freely altered. Replacing the native UTRs of the synthetic mRNA with the UTRs of
transcripts with exceptionally long half-lives, such as housekeeping genes, can confer
the same effect to the synthetic mRNA 137. Conversely, the inclusion of UTRs with
destabilizing elements can be used to reduce the half-life of the synthetic mRNA 138. In
addition, the inclusion of some UTRs has been found to increase the translation
efficiency without affecting the half-life of the synthetic mRNA 139.

Polyadenylation
In addition to 5’ capping, eukaryotic mRNA also receives a poly(A) tail during premRNA processing. The addition of the poly(A) tail to the synthetic mRNA is equally
important for efficient translation. The simplest means of polyadenylating a synthetic
mRNA is by including a stretch of adenines in the transcription template. Encoding the
poly(A) tail within template allows for direct control over the length of the tail, although
slippage of the RNA polymerase can produce slightly longer tails than encoded in the
template 140. In addition, direct encoding allows for production of the tail during
transcription. Alternatively, the poly(A) tail can be added post-transcriptionally by E. coli
poly(A)-polymerase using commercially available kits. This enzymatic addition generally
provides tails of 100 to 200 nucleotides in length.
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Figure 2.3. Structure of mRNA 5’ cap and cap analogs.
(A) The mRNA 5’ cap consists of 5’-5’ joining of m7G and the first transcribed
nucleotide, forming Cap0. Methylation of the 2’ hydroxyl of the first and second
nucleotides occurs to procures the Cap1 and Cap2, respectively. (B) Structure of the
m7GpppG cap analog. (C) Structure of the anti-reverse cap analog (ARCA), which has
an additional 3’ hydroxyl methylation compared to m7GpppG.
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However, the distribution of tail sizes within a single enzymatic polyadenylation
reaction varies much more than synthetic mRNAs with encoded poly(A) tails 140. A
consensus of the optimal poly(A) tail length has not been found, but generally tails
longer than 100 nucleotides are most effective 141.

Addition of Regulatory Elements
The flexible nature of the synthetic mRNAs allows for inclusion of elements that
specifically alter its expression. The localization of these regulatory elements in the
UTRs permits addition with minimal coding sequence perturbation. These elements can
be tailored and combined to increase the complexity of the regulatory circuits and direct
the expression of the synthetic mRNA in a more cell-specific or environmentally
responsive manner.

microRNA Switches
Placing miRNA target site (s) in the 3’ UTR of a reporter gene provides a simple
way to validate the target site. This strategy has been expanded to confer cell-selectivity
to plasmid and viral vectors by including target sites for miRNA that are highly
expressed by cells that are not the intended target of the vector 142. The same strategy
has also been applied to synthetic mRNAs, forming a miRNA switch. Studies utilizing
miRNA switches have shown that despite the rapid translation of synthetic mRNA,
silencing by endogenous miRNA is still effective 143. Furthermore, it was also discovered
that a single target site at the 5’ UTR is able to provide equivalent silencing to four
target sites in the 3’ UTR 144,145.
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Aptamers
In addition to specific sequence recognition mediated by Watson-Crick base
pairing, specific secondary structures, called aptamers, can be added to the UTR of
synthetic mRNA that are recognized by endogenous proteins. Inclusion of these
aptamer sequences can allow the construction of protein-responsive synthetic mRNAs
that are repressed by the presence of the aptamer-binding protein 146. Aptamers that
recognize small molecules, such as tetracycline or Hoechst dye, can also be inserted
near the start codon to block translation in the presence of their ligand 147,148. No ONswitch aptamers have yet been reported, likely due to the stabilization of aptamer
structure upon ligand binding impeding translational machinery.

Gene Circuits
Although the inclusion miRNA target sites and aptamers in synthetic mRNA only
provides a means of reducing translation, trans-regulatory effectors can be used to
invert these effects by constructing a gene circuit. The design of cell-, ligand-, and
environmental-responsive gene circuits is a rapidly growing subject in the field of
synthetic biology. Recent reports have demonstrated cell-specific expression of
reporters by miRNA-mediated silencing of an aptamer binding protein in a gene circuit
composed of only synthetic mRNA 149. Similar gene circuits have also been designed to
be responsive to small molecules like tetracyclin 150,151.
Perhaps the closest analog to an ON-switch aptamer is ligand-responsive
programmed ribosomal frameshifting (PRF), which is employed by viruses to induce a
specific frameshift during translation resulting in different open reading frame (ORF).
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PRF allows viruses to overlap multiple ORFs and reduces the size of the viral genome.
Placing a ligand-sensing aptamer overlapping the end of the PRF sequence, the PRF is
abolished in the presence of the ligand. Alternatively, introducing a hairpin structure
between the PRF signal and the aptamer disrupts both sequences in the absence of the
ligand. Binding of the ligand to the aptamer leads to destabilization of the hairpin and
induces the PRF. Multiple PRF signals can be incorporated into a single synthetic
mRNA, allowing for multiple inputs and outputs 152.

In vitro Protein Complexing
Recent work has shown that complexing synthetic mRNA with the eIF4E protein
prior to encapsulation in a nanocarrier increased production. Part of this increased
translation may be due to a measured increase in the stability of the mRNA-eIF4E
complexes over uncomplexed mRNA. However, the enhancement by eIF4E was
dependent on the polyamine used to form the nanocarrier 153. Further investigations are
needed to test the applicability of in vitro protein complexing with other regulatory
protein and nanocarrier systems.

Circular mRNA
Although eukaryotic mRNA is positioned in a nearly circular manner during
translation, ribosomes must be recycled and reassembled to complete additional rounds
of translation. Joining of the 5’ and 3’ ends of uncapped, untailed synthetic mRNA has
been shown to produce circular mRNA. Translation of these circular mRNAs occurs in
human cells even in the absence of an IRES sequence 154. Furthermore, the circular
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mRNAs exhibit increased resistance to RNase degradation due to the lack of terminal
nucleotides for exonuclease to attack 154. Recent work has demonstrated the efficacy of
circularizing mRNA for increasing the production of recombinant proteins by removing
the stop codon and introducing self-cleaving peptides 155. Other work has shown that
fully complementary miRNA target sites can direct cleavage of circular RNA, which
could be exploited to create circular versions miRNA switches to increase protein
production 156.

Self-replicating mRNAs
The short lifetime of synthetic mRNAs necessitates repeated treatments to
maintain protein expression. However, exploitation of alphaviral genomic RNA allows for
the production of self-replicating synthetic mRNAs. The alphavirus family are plusstrand RNA viruses with genomes that encoded two polyproteins: the 5’ non-structural
proteins (NSP) produced by cap-dependent translation and the 3’ structural proteins
produced by translation from a subgenomic mRNA 157. The NSPs transcribe the minusstrand RNA necessary for genome replication and subgenomic mRNA transcription.
The compartmentalization of the structural proteins into the subgenomic mRNA allows
for their replacement with a gene of interest without altering the replicative capacity of
the alphaviral genomic RNA. The resulting self-replicating mRNA produces very durable
expression, far surpassing that regular synthetic mRNA and plasmid vectors. In ancillary
experiments performed during the work reported in this dissertation, expression of a
self-replicating green fluorescent protein (GFP) mRNA with a built-in puromycin
resistance gene was observed in adherent-human embryonic kidney (Ad-HEK293) cells
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out to three months (90 days) after transfection (Figure 2.4). These self-replicating
mRNAs can also be regulated as part of a gene circuit 158.

Synthesis of synthetic mRNAs
One of the benefits of synthetic mRNAs over other gene vectors is their ease of
production. While it is possible to synthesize mRNAs base-by-base via nucleotide
synthesizers, efficient production is limited to mRNAs with fewer than 100 bases due to
the compounding effect of imperfect coupling efficiency. Therefore, synthetic mRNAs
are usually generated by IVT from a DNA template. The resulting mRNA product must
also be purified to remove the DNA template, reaction enzymes, free nucleotides, and
potentially immunogenic dsRNA contaminants.

Enzymatic synthesis by in vitro transcription
IVT is typically performed using a T7 or SP6 bacteriophage RNA polymerase.
The structure of these two polymerases is highly similar, but each polymerase requires
a specific and short promoter for initiation of transcription. Transcription continues until
the polymerases reach a terminator sequence. However, both T7 and SP6 polymerase
exhibit a very high rate of readthrough transcription 159. This readthrough transcription is
fundamental to establishing the stoichiometric ratio of the bacteriophage genes and is
driven by the high processivity of the RNA polymerases 160. The processivity of the
polymerases also enables IVT reactions to be scaled up to produce large quantities of
synthetic mRNA.
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Template Optimization for in vitro transcription
Both T7 and SP6 are DNA-dependent RNA polymerases, and therefore synthetic
mRNA must first be constructed in a DNA template. Both plasmids and polymerase
chain reaction (PCR) dsDNA products can be used for IVT. Because of the previously
discussed readthrough transcription common to T7 and SP6, the use of an intact
plasmid template leads to generation of a heterogenous pool of products. Products of a
defined length are produced from plasmids that have been cut with a restriction enzyme
immediately downstream of the synthetic mRNA sequence. However, a restriction
enzyme that produces a blunt end or 5’ overhang should be used to prevent the
polymerase from reinitiating on a transcript and producing larger than expected RNA 161.
If a PCR product is to be used as the template for IVT, gel purification after
electrophoresis is recommend to ensure proper product size.
Optimization of the DNA template may be required for efficient IVT. The
presence of T7 or SP6 terminator sequences in the template can lead to production of
shorter than expected and heterogenous RNA products. The specificity of the terminator
sequences enables their removal with only a few changes to the DNA template
sequence. In addition, highly structured DNA elements like G-quadruplexes can block
elongation of the RNA transcripts 162. These structured regions can also be disrupted by
altering only a few nucleotides.
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Figure 2.4. Duration of self-replicating GFP mRNA expression in Ad-HEK293 cells.
Flow cytometry analysis of GFP expression in Ad-HEK293 cells after transfection with a
self-replicating mRNA encoding GFP and a puromycin resistance gene. Cells were
maintained in puromycin-supplemented medium for the duration of the experiment.
Experiment was stopped on day 91 post-transfection.
Synthetic mRNA Purification
Purification of synthetic mRNA is necessary to ensure maximum efficacy and
minimal immunogenicity. Many RNA purification kits are commercially available, but
these kits can be replaced and supplemented with other techniques. The overall goal of
these steps is the removal of template DNA, free nucleotides, reaction enzymes, and
dsRNA products.
Ethanol, isopropanol, or a mixture of phenolic acid and chloroform are commonly
used to concentrate nucleic acids and remove of protein contaminants. The inclusion of
high concentrations of salts facilitates precipitation of the nucleic acids. Ammonium
acetate is commonly used for purifying mRNA products from IVT as it is capable of
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specifically precipitating RNA, leaving protein, DNA, and free nucleotides in solution.
Lithium chloride is also suitable for mRNA purification but requires a higher
concentration of mRNA for effective precipitation 163.

Elimination of double-stranded RNA
Due to the immunogenicity of dsRNA, removal of dsRNA products may be
required. Comprehensive removal of dsRNA can be accomplished by fractionation
using high performance liquid chomotography (HPLC). HPLC purification also allows for
removal of incorrectly sized ssRNA products if needed 85. Recently, it has been shown
that dsRNA can be specifically removed by centrifugation through a cellulose filled spin
column, allowing for much more rapid purification without the need for specialized HPLC
equipment 164.

Therapeutic Applications of synthetic mRNA
The advantages of synthetic mRNA over plasmid or viral vectors, in conjunction
with the recent advances in the increasing the efficacy and regulation of synthetic
mRNA, have poised this promising class of biological drugs to revolutionize gene
therapies. The rapid advances in the past decade have produced a plethora of
biotechnology companies focused on the therapeutic application of synthetic mRNA. In
addition, the initial successes seen so far have drawn the attention of traditional
pharmaceutical companies which have begun investing in mRNA therapeutics. There
are currently over 45 ongoing clinical trials involving delivery of synthetic mRNA to treat
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a variety of diseases and disorders.

Protein Replacement
The most basic therapeutic application for synthetic mRNA is protein
replacement. Initial studies utilizing synthetic mRNA were able to produce appreciable
amounts of protein after injection in to animals 165. Synthetic mRNA was even shown to
provide better results than recombinant protein therapies in a mouse model of Factor
XI-deficient hemophilia B 166,167. However, only a few clinical trials involving delivery of
synthetic mRNA for protein replacement are currently active.
A Phase II trial investigating the delivery of vascular endothelial growth factor A
(VEGF-A) mRNA via epicardial injection during coronary bypass surgery
(NCT03370887) is currently recruiting patients (Table 2.1). The preclinical studies using
this strategy in a myocardial infarction model in rodents and swine has demonstrated a
significant increase in revascularization of the infarct area and decreased fibrosis 168.
Another clinical trial for VEGF mRNA is likely to be started to investing the efficacy in
improving wound healing in diabetic individuals based on preclinical results in mice and
successful completion of a Phase I safety study (NCT02935712) 169.
A Phase I/II clinical trial (NCT03375047) is also underway for the treatment of
cystic fibrosis with nebulized synthetic mRNA. Preclinical results in mice have indicated
that up to 55% of normal chloride efflux could be restored by nebulization of cystic
fibrosis transmembrane conductance regulator (CFTR) mRNA. Approval was recently
given to assess the safety of multiple dosing of enrolled patients.
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A similar Phase I/II clinical trial (NCT03767270) for treatment of orinithine
transcarbamylase (OTC) deficiency, a hereditary disorder that leads to accumulation of
ammonia in the blood after protein metabolism, has been submitted. Unlike the previous
trials, NCT03767270 involves systemic administration of the synthetic mRNA to target
the liver. However, the trial was placed on hold prior to patient enrollment until more
preclinical data can be shown.

Vaccines
The properties of synthetic mRNA, particularly the rapid and transient expression
of the encoded proteins, make it an ideal platform for vaccine development. Synthetic
mRNA vaccines have shown promising preclinical results for a wide variety of infectious
diseases such as: influenza, rabies, chikungunya, HIV, Ebola, and Toxoplasmosis
gondii 170 . The ability to quickly generate antigen-encoding synthetic mRNA accelerates
the development of mRNA vaccines for emerging diseases. For example, the 2016
outbreak of Zika virus prompted the development of mRNA-based vaccines by two
independent groups by early 2017 171,172. The optimal design of the synthetic mRNA
used for vaccines remains to be determined. Self-replicating mRNAs are frequently
used as they allow for durable expression and robust induction of antigen-specific
antibodies 173. Synthetic mRNA vaccines can also be made self-adjuvanted by using
unmodified mRNA that stimulates humoral immune responses via TLR7 174.
Clinical trials for synthetic mRNA vaccines against rabies virus (NCT03713086),
metapneumovirus/parainfluenza (NCT03392389), cytomegalovirus (NCT03382405),
chikungunya virus (NCT03829384), and influenza (NCT03345043) are currently
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ongoing (Table 2.1). While preliminary results indicate that these treatments are safe,
the protective effects of these vaccines have been found to vary significantly depending
on the delivery method (i.e. needle or needle-free) 175.
Synthetic mRNA can also be delivered to ex vivo to a patient’s dendritic cells,
targeting them to the encoded antigen, before reinjection. Numerous clinical trials for
HIV using mRNA-pulsed autologous dendritic cells (NCT00833781, NCT00672191,
NCT01069809) found expected increases in antigen-specific T-cell response but
observed no clinical benefit or decrease in viral load 176,177.

Cancer Vaccines
The flexibility of synthetic mRNA can also be utilized to encode tumor-specific
antigens for vaccines against cancer. Unlike the prophylactic vaccines developed for
infectious disease, cancer vaccines are designed to induce an immune response to
tumor associated antigens (TAA) that are enriched on the surface of cancer cells or
neoantigens that arise from somatic mutations. Immunotherapy allows for more specific
targeting of cancer cells compared to traditional chemotherapies, greatly reducing the
side effects common to anti-neoplastic therapeutics. The use of synthetic mRNA in
cancer vaccines is almost exclusively in autologous dendritic cell therapies with
numerous trials underway using this technique, including 3 Phase III trials (Table 2.1).
Initial results of these trials have been promising and were bolstered by FDA approval of
a peptide-based dendritic cell therapy (sipuleucel-T) in 2010.

Cellular Reprogramming
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Reprogramming of somatic cells into pluripotent stems has many clinical
applications, such as autologous stem cell therapies, drug screening, and disease
modeling. Traditional generation of induced pluripotent stem cells (iPSC) relies on
ectopic expression of the four Yamanaka factors: OCT4, KLF4, SOX2, and cMYC.
Plasmid transfection and viral transduction are frequently used to produce iPSCs from a
variety of somatic cell types. Synthetic mRNA is also capable of inducing cellular
reprogramming but requires multiple transfections to maintain expression of the
Yamanaka factors 178,179. However, incorporating all of the Yamanaka factors and a
puromycin selection gene into a single self-replicating synthetic mRNA allowed for
efficient iPSC generation with only a single treatment of the mRNA. Encoding all of the
factors on a single transcript also ensures a consistent ratio of expression for each
factor 180. Optimization of synthetic mRNA-mediated reprogramming has increased the
efficiency to above 90%, allowing for iPSC generation from a very small number of
primary cells 181. Synthetic mRNA can also be used to efficiently differentiate iPSCs into
the desired somatic cell type 182.
Genome Editing
Correcting a genetic defect is the ultimate form of gene therapy. The recent
discovery of the CRISPR/Cas9 nuclease system has caused a surge of genome editing
research. The key advantage provided by Cas9 nucleases over older technologies such
as Zinc-finger nucleases (ZFN) or transcription activator-like effector nucleases
(TALEN) is the recognition of target sites by Watson-Crick base pairing via a guide RNA
rather than direct recognition by the nuclease.
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Various delivery strategies have been developed for all of the available gene
editing systems. For clinical applications the duration of nuclease expression must be
balanced by the need for sustained nuclease activity to ensure on-target correction and
minimized expression to prevent off-target activity 183. There has been a recent shift
toward delivery of synthetic mRNA encoding Cas9 rather viral or plasmid delivery 184,185.
Gene circuits have also been designed that could be used to further control the
expression and activity of Cas9 to reduce off-target effects 186.
Synthetic mRNA encoding Cas9 and IVT guide RNA have been shown to
produce durable knockdown of a liver-specific gene in vivo following a single dose 187.
Synthetic mRNA encoding a CCR5-targeting ZFN (SB-728) is currently in use in two
clinical trials (NCT02500849, NCT02388594) aimed at establishing a HIV-resistant T
cell population in patients undergoing retroviral therapies 188. However, gene correction
requires a DNA repair template, which precludes the development of a synthetic RNAonly system. Despite this shortcoming, synthetic mRNA encoding nucleases could be
used to reduce off-target effects in the ex vivo gene editing performed in a number of
ongoing clinical trials (Table 2.1).
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Table 2.1 Ongoing and recently completed clinical trials utilizing synthetic mRNA.
Trial ID

Phase

Status

Application
Methylmalonic
Acidemia
Ornithine
Transcarbamylase
Deficiency

Method

Gene

IV Infusion

MUT

IV Infusion

OTC

Protein Replacement
NCT03810690

I/II

Not yet
recruiting

NCT03767270

I/II

Not yet
recruiting

NCT03375047

I/II

Recruiting

Cystic Fibrosis

Nebulization

CFTR

NCT03370887

II

Recruiting

Heart Failure

Intracardial
Injection

VEGF-A

Infections Disease Vaccines
NCT03829384

I

Not yet
recruiting

Chikungunya Virus

IM Injection

Anti-CV
antibody

NCT03713086

I

Recruiting

Rabies Virus

IM Injection

RABV-G

NCT03619278

I/II

Recruiting

HIV

mRNA-pulsed
dendritic cells

NCT03382405

I

Recruiting

Cytomegalovirus

IM Injection

NCT03392389

I

Metapneumovirus
and Parainfluenza

IM Injection

NCT03345043

I

H7N9 Influenza

IM Injection

ND

NCT03325075

I

Chikungunya Virus

IM Injection

ND

NCT03076385

I

H10N8 Influenza

IM Injection

ND

NCT03014089

I

Active, not
recruiting
Active, not
recruiting
Active, not
recruiting
Active, not
recruiting
Active, not
recruiting

TriMix and
HIV antigens
CMV-gB and
CMV-pp65
hMPV-F and
PV3-F

Zika Virus

IM Injection

ND

NCT02500849

I

Completed

HIV

NCT02413645

I

Completed

HIV

NCT02388594

I

Completed

HIV

NCT02241135

I

Completed

Rabies virus

IM Injection

RABV-G

NCT00833781

I/II

Completed

HIV

mRNA-pulsed
dendritic cells

HIV Gag and
Nef
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ZFN edited Tcells
mRNA-pulsed
dendritic cells
ZFN edited Tcells

ZFN to CCR5
TriMix and
HIV antigens
ZFN to CCR5

Table 2.1 (Continued)
Cancer Immunotherapies
Not yet
recruiting
Not yet
recruiting

Glioblastoma

mRNA-pulsed
dendritic cells

Melanoma

ND

NCT03927222

II

NCT03897881

II

NCT03871348

I

Recruiting

Metastatic Melanoma

NCT03788083

I

Recruiting

Breast Cancer

NCT03739931

I

Recruiting

Solid Tumors or
Lymphoma

NCT03688178

II

NCT03615404

I

NCT03548571

II/III

Recruiting

Glioblastoma

mRNA-pulsed
dendritic cells

Survivin,
hTERT,
tumor mRNA

NCT03418480

I/II

Recruiting

Multiple Carcinomas,

IM Injection

HPV antigen

NCT03415100

I

Recruiting

Metastatic Solid
Tumors

NCT03323398

I/II

Recruiting

Solid Tumors or
Lymphoma

mRNA
programmed
CAR-NK cells
Intratumoral
Injection

NCT03313778

I

Recruiting

Solid Tumors

ND

NCT03289962

I

Recruiting

Solid Tumors

IV Infusion

Not yet
recruiting
Active, not
recruiting

Glioblastoma
Glioblastoma

Myelodysplastic
Syndromes,
Acute Myeloid
Leukemia
Brain Cancer,
Neoplasm
Metastases

NCT03083054

I/II

Recruiting

NCT02808416

I/II

Recruiting

NCT02808364

I/II

Recruiting

Glioblastoma

NCT02709616

I/II

Recruiting

Glioblastoma
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Intratumoral
Injection
Intratumoral
Injection
Intratumoral
Injection
mRNA-pulsed
dendritic cells
mRNA-pulsed
dendritic cells

mRNA-pulsed
dendritic cells
mRNA-pulsed
dendritic cells
and PBMC
mRNA-pulsed
dendritic cells
and PBMC
mRNA-pulsed
dendritic cells
and PBMC

CMV-pp65
Variable
(PCV)
Undisclosed
Cytokine
TriMix
OX40L,
IL-23,
IL36𝛾
CMV-pp65
CMV-pp65

CAR against
NKG2D
OX40L
Variable
(PCV)
Variable
(PCV)
WT1
Variable
(PCV)
Variable
(PCV)
Variable
(PCV)

Table 2.1 (Continued)
Cancer Immunotherapies (Continued)
NCT02692976

II

Active, not
recruiting

NCT02649829

I/II

Recruiting

Malignant Pleural
Mesothelioma

NCT02649582

I/II

Recruiting

Glioblastoma

NCT02529072

I

Active, not
recruiting

NCT02528682

I/II

Recruiting

Astrocytoma,
Glioblastoma
Hematological
Malignancies

NCT02465268

II

Recruiting

NCT02452307

I/II

NCT02405338

I/II

NCT02366728

II

NCT02035956

I

NCT01995708

I

Active, not
recruiting

Multiple Myeloma

NCT01686334

II

Recruiting

Acute Myeloid
Leukemia

NCT01456104

I

Active,not
recruiting

Melanoma

NCT01197625

I/II

Active, not
recruiting

Prostate Cancer

Active, not
recruiting
Active, not
recruiting
Active, not
recruiting
Active, not
recruiting

Prostate Cancer

Glioblastoma

ND
WT1
WT1
CMV-pp65
MiHA
CMV-pp65

Prostate Cancer

SQ injection

ND

Acute Myeloid
Leukemia
Glioblastoma,
Astrocytoma

mRNA-pulsed
dendritic cells
mRNA-pulsed
dendritic cells
Intranodal
injection

WT1,
PRAME

Melanoma

Active, not
Brain Cancer
recruiting
ND: Not disclosed; PCV: Personalized Cancer Vaccine
NCT00639639

Peptide-pulsed
dendritic cells
with mRNA
adjuvant
mRNA-pulsed
dendritic cells
mRNA-pulsed
dendritic cells
mRNA-pulsed
dendritic cells
mRNA-pulsed
dendritic cells
mRNA-pulsed
dendritic cells

I
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mRNA-pulsed
dendritic cells
mRNA-pulsed
dendritic cells
mRNA-pulsed
dendritic cells
mRNA-pulsed
dendritic cells
mRNA-pulsed
dendritic cells

CMV-pp65
Variable
(PCV)
CT7,
MAGE,
WT1
WT1
Variable
(PCV)
Survivin,
hTERT,
tumor mRNA
CMV-pp65

Chapter 3
Delivery of synthetic mRNA in vitro and in vivo
Mechanisms of Cellular Uptake
The cellular membrane provides a vital barrier between the highly regulated
cytoplasm and the extracellular environment. While small molecules are able to pass
through specialized channel proteins that span the cellular membrane, larger molecules
like proteins and highly-charged molecules require active transport to enter the cytosol.
This active transport often involves the formation of specialized vesicles called
endosomes that encapsulate a small volume of the extracellular environment for further
processing inside the cell.

Receptor-mediated Endocytosis
The selective cellular uptake of large molecules, such as growth factors or lowdensity lipoprotein (LDL), is mediated by binding to a cognate receptor. The receptor’s
intracellular domain engage adaptor proteins complexes that recruit clathrin triskelia.
Interestingly, the binding of adaptor proteins is not dependent on ligand binding to the
receptor. The most well studied adaptor protein is Adaptor protein 2 (AP2), which
composed of heterotetramer of α, β2, μ2, and σ2 subunits. Upon binding to the cytosolic
domains of receptor proteins, AP2 undergoes a conformational change stabilized by
interaction with Phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) lipids in the plasma
membrane and exposes the clathrin-binding site on the β2 subunit 189,190. A single
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clathrin triskelion consists of three interlocking spirals, each formed by a complex of a
single heavy chain and light chain. Individual clathrin triskelia interact to form a lattice or
cage anchored to the plasma membrane by AP2. However, both of these interactions
are relatively unstable and allow for shuttling of clathrin to and from the lattice. Cargo
binding to the receptors stabilizes the interaction of AP2 with the cytosolic domain and
promotes retention of associated clathrin. Proximity of multiple AP2-bound receptors
promotes the formation of a clathrin-coated pit (CCP), which has an average diameter
of ~40 nm. CCP formation is driven by the intermolecular forces between clathrin
triskelia that arrange themselves into a truncated icosahedron. As the CCP invaginates,
the clathrin triskelia closest to the undeformed cell membrane assemble without binding
to AP2, leading to AP2 enrichment at the bottom of the invagination 191. While a CCP
can spontaneously form de novo due to stoichiometric proximity of receptors, the
duration of such CCP is much lower than those formed with ligand-bound receptors 192.
Cleavage of the CCP to form a clathrin-coated vesicle (CCV) requires the
pinching of the top of the CCP. The mechanism responsible for this are largely unknown
but are dependent on the GTPase activity of dynamin. Inhibition of the GTPase activity
of dynamin blocks endosomal constriction and CCV scission, resulting in accumulation
of unconstricted or totally constricted CCP 193. Once cleaved from the membrane, the
clathrin coating of CCV is rapidly removed by heat-shock cognate protein (Hsc70) 194.
The uncoated vesicles are then trafficked to sorting endosomes to separate the
receptors and the bound cargo.
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Caveolae
Caveolae, like CCP, are invaginations in the cell membrane that can pinched off
to form endocytic vesicles. However, caveolae also play a role in a variety of other
cellular processes, such as mechanosensing, intercellular signaling, and lipid
metabolism 195–197. Caveolae are ~70 nm in diameter and characterized by the presence
of caveolin proteins embedded in the lipid bilayer. Caveolin-1 (CAV-1) was the first
caveolin protein identified and has been shown to enrich caveolae with cholesterol
though direct binding at the C-terminus. CAV-1 enriched membrane domains are
stabilized by the binding of Cavin1, which also interacts with PI(4,5)P2. The binding of
Cavin1 is thought to induce the invagination of caveolae, though exact mechanisms
remain unclear 198. Scission of caveolae from the plasma membrane, like CCV, is driven
by the GTPase activity of dynamin 199. The endocytic caveolae vesicle then fuses with
early endosomes for further processing, although there have been reports of clusters of
endocytic caveolae vesicles distinct from endosomes 200.

Macropinocytosis
Macropinocytosis, encompasses all endocytic processes that are clathrin- and
caveolae-independent and occurs in all cell types. The formation of invaginations during
macropinocytosis is driven by the formation of a distinct ring of filamentous actin (Factin) 201. These contractile F-actin rings can arise spontaneously or can be formed by
closure of circular membrane ruffles 202,203. The expansion of the F-actin ring outward
from the forms the overlying plasma membrane into cup, eventually creating a tight
neck similar to that of other endocytic vesicles. However, the mechanism of
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macropinosome scission is not currently known, but it is known to occur independent of
dynamin activity 204. Once fully cleaved from the membrane, macropinosomes enter the
endosomal trafficking pathway along with CCV and endocytic caveolar vesicles.

Maturation of Endocytic Vesicles
Most endocytic vesicles are processed through the endosomal pathway after
membrane scission. This pathway serves a hub of intracellular trafficking and can sort
endocytosed particles for degradation, cytosolic release, or recycling to the plasma
membrane. The endpoint of endosomal trafficking is largely determined by binding of
various proteins markers, particularly members of the Rab GTPase family, and
conversion of phospholipids in the endosomal membrane during the process of
endosomal maturation.

Early Endosomes
The first stage of endosomal trafficking is characterized by fusion of multiple
vesicles of the same type to form an early endosome. The early endosome serves as
both a buffer between nascent vesicles and the primary cargo sorting compartment. The
amount of membrane, number of receptors, and enclosed volume of the incoming
vesicles necessitates rapid recycling from the early endosome back to the plasma
membrane by Rab4. The release of cargo from the cognate receptor is facilitated by the
decreased pH (~6.5) in the early endosome, which is driven by the vacuolar H+-ATPase
(V-ATPase). The positive charge of the transported protons is offset by the presence of
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vacuolar chloride channels, minimizing the electrochemical gradient across the
endosomal membrane 205.
The early endosome is characterized by the accumulation of Rab5 on the outside
of the endosomal membrane. Rab5 recruits phosphatidylinositol 3-kinase to the
endosomal membrane which converts phosphatidylinositol (PtdIns) to PtdIns(3)P
(PI(3)P). PI(3)P is recognized by Endosomal Sorting Complexes Required for Transport
(ESCRT)-0, which also binds to the intracellular domains of endocytosed receptors
marked for degradation. Subsequent recruitment of ESCRT-1, 2, and 3 localizes the
marked receptors into invaginations within the early endosome. Inward deformation of
the endosomal membrane by the ESCRTs leads to the formation of an intraluminal
vesicle 206.

Late Endosomes/Lysosomes
The maturation of early endosomes to late endosomes is marked by a switch in
the binding of Rab5 to Rab7. Recent work shows that this change is mediated by
recruitment of Rab7 by the binding of SAND-1 to Rab5 207. In addition, the PI(3)P in the
endosomal membrane can be further phosphorylated to PI(3,5)P2 by PIKFYVE, and
accumulation of PI(3,5)P2 reduces further binding of nascent endocytic vesicles to the
maturing endosome 208. During the maturation process the endosome continues to
acidify, reaching a pH of ~5.5 in the late endosome.
The maturing endosome is transported along the cytoskeleton toward the
nucleus. Along the way vesicles containing various lysosomal acid hydrolases fuse with
the endosome and being degrading the endosomal cargo. This degradation can be
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accelerated by fusion of the endosome with established secondary lysosomes 209. After
degradation, the excess membrane of the lysosome is recycled back to the Golgi
thereby reforming the secondary lysosome 210.

mRNA Delivery Methods
The delivery of synthetic mRNA is the largest barrier to wider clinical
applications. There are two major problems that must be resolved: delivery of synthetic
mRNA to the target organ/tissue/cells and endosomal escape. To overcome these
obstacles, a variety of methods have been developed to transfect synthetic mRNA into
cells.

Physical Transfection Methods
The cellular membrane prevents passive diffusion of mRNA molecules into cells
due to their large size and high negative charge. Because synthetic mRNA need only to
access the cytoplasm to produce their effect, bypassing the cell membrane can be an
effective method of delivery.

Electroporation
Electroporation is widely used in the laboratory setting to deliver DNA into cells.
The generation of a strong local electric field forms pores in the cellular membrane
which allows large molecules to diffuse into the cell. The efficiency of in vitro
electroporation is very high due the ability to concentrate the recipient cells and payload
nucleic acid in a very small volume. However, the stress of the electroporation results in
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a high rate of cell death, necessitating the use of large numbers of cells to recover a
viable population of transfected cells.
In addition to in vitro applications, electroporation has also been demonstrated to
effectively deliver nucleic acid payloads in vivo 211. The focal application of the electric
field allows for very precise targeting of payload nucleic acids. However, the small size
of the transfected area reduces the feasibility of such a transfection method in larger
organisms and would necessitate multiple applications to cover a significant area.
Electroporation has been widely employed in ex vivo transfection of autologous
cells. Many clinical trials for cancer vaccines employ dendritic cells that are pulsed with
mRNA via electroporation (Table 2.1). Electroporation is well suited for such therapies
because the cells collected from the patient can be expanded before and after
transfection.

Biolistic Delivery
An alternative to electroporation for topical delivery of nucleic acids is the use a
biolistic delivery system, commonly referred to as a “gene gun”. This method of
transfection utilizes nucleic acids complexed to inert metal, typically gold, nanoparticles
that are accelerated high speeds by compressed gas. The fast-moving nanoparticles
are capable of penetrating through cell membranes.
Biolistic delivery is commonly employed in agriculture research 212. Like in vivo
electroporation, biolisitic delivery is well suited for applications that need only a localized
expression of the delivered nucleic acid to produce the desired effect. Biolisitic delivery
of DNA vaccines have shown some efficacy, but the immune response to these
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vaccines differs from those delivered by intramuscular injection 213,214. Topical (<1 mm)
transfection of mRNA into the skin or kidney has also been demonstrated using a gene
gun in a rat model, along with a potential application in accelerating wound healing 215.

Microinjection
Synthetic mRNA can also be directly injected in to the cytoplasm of a cell using a
micropipette. Due to the intensive labor and low throughput of this technique, it typically
used to deliver synthetic mRNA encoding Cas9 to perform gene editing in zygotes 216.

Nanoparticle Delivery Platforms
While mechanical transfection methods are sufficient for localized transfection of
synthetic mRNA, systemic deliver poses additional challenges. Firstly, the stability of
mRNA in the bloodstream or extracellular interstitium is extremely low due to the
presence of extracellular RNAse. Therefore, it is necessary to shield the synthetic
mRNA from the surrounding environment in a nanoparticle by encapsulating the
payload mRNA away from the environment or by winding of the mRNA within the
nanoparticle structure 217. Secondly, the nanoparticles and their synthetic mRNA
payload must be capable of entering cells . Unlike mechanical transfection methods,
nanoparticles must be taken up by cells via endocytosis. Efficient uptake of
nanoparticles by cells is dependent on the both the hydrodynamic diameter and the
surface charge of the nanoparticle. Internalization can also be affected by recognition by
cell-surface receptors. Lastly, once the nanoparticles are endocytosed, the synthetic
mRNA payload must be released to the cytoplasm. This requires both disassembly of
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the nanoparticle and escape from the endosome. Endosomal escape in particular
remains a significant challenge for most of the synthetic mRNA delivery platforms
currently in use, with typical endosomal escape rates averaging approximately 2% 218.
Nanoparticle design must also consider the balance between the stability of
nanoparticles in the extracellular space and the ability to release the payload from the
mRNA once inside of cells.
The similarity of synthetic mRNA and siRNA has allowed the results from the
more mature field of siRNA therapeutics to guide the development of mRNA delivery
platforms. There are two classes of nanoparticles that are the focus of intense preclinical research, lipid and polymer-based nanoparticles. Both systems have received
approval from the US Food and Drug Administration (FDA), though only one lipid
nanoparticle has been approved for delivery of a therapeutic RNA (Patisiran). However,
the variety of compositions possible when designing these delivery systems has begun
to blur the lines between these categories.

Lipid Nanoparticles
Lipid nanoparticles (LNP) are the most well-studied delivery platform for synthetic
mRNA delivery. The structure of LNP is defined by the formation of a lipid bilayer
around the nucleic acid containing core. Altering the composition of the bilayer is the
focus of most LNP development strategies. The earliest LNP were formed from bilayers
containing a mixture of cationic and neutral lipids, N-[1-(2,3-Dioleyloxy)propyl]J-N,N,Ntrimethylammonium Chloride (DOTMA) and dioleoylphosphatidylethanolamine (DOPE)
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219

. The positively charged head of the cationic lipid allows electrostatic interaction with

the negatively charged backbone of nucleic acids and promotes efficient encapsulation.
The efficacy of these LNPs has been increased by adding stabilizing and
shielding components to the lipid bilayer. Cholesterol is also incorporated during LNP
formation to increase the stability of the lipid bilayer. Helper lipids bearing polyethylene
glycol (PEG)-conjugated lipids are also frequently used to form the outer layer of the
LNP. The PEGylated lipids play a key role in the determination of LNP size due to steric
stabilization by the PEGylated head groups.
Due to undesirable interaction with negatively charged serum proteins and
subsequently rapid clearance the use of cationic lipids for in vivo applications is very
limited. To overcome these effects, permanently cationic lipids have largely been
replaced with ionizable lipids that are cationic only in acidic environments. As a
consequence of this inducible charging, formation of LNP with ionizable lipids must be
carried out in an acidic environment. To facilitate efficient packaging of the payload
nucleic acid, LNPs are typically constructed using microfluidic mixing. This technique
allows for precise control over the ratio of ionizable lipid, helper lipids, and payload, as
well as the timing of the component addition 220. A wide variety of ionizable lipids have
been developed, but the details the composition of LNP in clinical development by
various biotechnology companies are proprietary information.
The positive charge of LNP facilitates their interaction with the negatively
charged membranes of cells, which can facilitate their uptake by endocytosis. Once in
contact with a cellular membrane, the cationic lipids or protonated ionizable lipids are
induced to flip between the membranes by anionic lipids in the cellular phospholipid
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bilayer. The electrostatic interaction of the cationic and anionic lipid head groups, alters
the geometry of the hydrophilic tails, and induces the adoption of hexagonal structure
that has been shown to destabilize the endosomes 221. However, uptake of LNP induces
a variety of cytotoxic effects, including vacuolization of the cell and reduced proliferation
222

.

Polymeric Nanoparticles and Nanomicelles
Nucleic acids can also be packaged by electrostatic interaction with polymers.
Polyethylenimine (PEI) is the prototypical polymeric transfection reagent and has been
widely used for in vitro transfection of DNA in the laboratory settings. PEI can be
produced with or without branching and at various molecular weights. The size and
transfectability of PEI nanoparticles is dependent on the structure of the PEI and the
conditions of nanoparticle formation 223. In particular, increasing the molecular weight of
PEI leads to formation of smaller nanoparticles due to the increased positive charge
carried by the PEI polymer 224. In addition, branched PEI nanoparticles are more
transfective in vitro while linear PEI nanoparticles are more transfective in vivo 225.
Regardless of the structure of the PEI used, the resulting nanoparticles are formed by
condensing of nucleic acids rather than encapsulation.
In contrast, the encapsulation of nucleic acids into a nanomicelle can be
achieved using amphiphilic co-polymers that contain both hydrophilic hydrophobic
domains, such as PEG-polyaspartamide 226. Endosomal escape of polymeric
nanoparticles and nanomicelles is due to osmotic swelling driven by “proton sponging”,
which draws additional chloride ions and subsequently water into the acidifying
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endosome. One drawback of polymeric nanoparticles and nanomicelles is the
persistence of the polymer after payload delivery, whose accumulation can induce
apoptosis in cells 227. However, degradable polymers or derivatives can be used to
reduce the accumulation and associated toxicity 228. Recent work has demonstrated the
utility of encapsulating a polymeric nanoparticle in a lipid bilayer to form a hybrid
nanoparticle 229.

Cell Penetrating Peptides
Cell penetrating peptides (CPP) have received little attention as a delivery
platform for synthetic mRNA. CPP are diverse class of proteins and peptides that
possess the ability to translocate across or disrupt the integrity of phospholipid bilayers
230

. For cargo delivery, CPP are typically covalently linked to their cargo. Such a linkage

is suitable delivery of siRNA and miRNA antagonists since these systems utilize an
inactive passenger strand of RNA, but covalent linkage to an mRNA would likely disrupt
translation.
Cationic and amphipathic CPP have been shown to form non-covalent
electrostatic interactions with the negatively-charged phosphodiester backbone of RNA
and DNA which can enable their delivery into cells 231,232. Most of these CPP are
permanently charged due to the presence of arginine and lysine residues, which
stabilizes their interaction with nucleic acids. Excessive stabilization can prevent CPP
from effectively delivering their cargo due to slow disassembly of the CPP-nucleic acid
complex and therefore poor endosomal escape, necessitating the use of
endosomolytics such as chloroquine 233.
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Alternatively, CPP that are not designed to interact with nucleic acids have been
incorporated into lipid or polymeric nanoparticles to increase their endosomal escape.
Melittin, a pore-forming CPP that is the primary component of bee venom, has been
shown to be particularly effective when employed in such a way 234. Melittin has also
been explored as a cytotoxic agent for treating cancer via delivery in perfluorocarbon
nanoparticles 235,236. The strong lytic activity of melittin can produce significant cell
death, but the inclusion of pH-sensitive protecting groups that limit melittin’s activity until
it reaches the endosome ameliorated this cytotoxicity 237. This pH-sensitive melittin was
employed as an endosomal escape adjuvant by Arrowhead Pharmaceuticals in a
clinical trial for an siRNA treatment for Hepatitis B infection (NCT02452528).
Unfortunately, even the pH-sensitive form of melittin proved hepatotoxic at high doses,
and the death of non-human primates in pre-clinical studies prompted the FDA to halt
the ongoing clinical trial. Recently, Arrowhead Pharmaceuticals has resumed clinical
trials using this system via subcutaneous delivery (NCT03365947).
Recent work has shown that truncated forms of melittin exhibit reduced lytic
activity 238. These melittin-derived peptides could insert into the membrane of liposomes
and perfluorocarbon nanoparticles to act as an anchor for surface conjugates, such
VCAM-1 targeting ligands 239. Further modification of these peptides that added a pHsensitive cationic charge on the C-terminal end of the peptide (p5RHH) enabled the
electrostatic conjugation of the peptide to an siRNA cargo 240. The inclusion of pHsensitive histidine residues allowed the p5RHH-siRNA nanoparticles to disassemble in
acidifying endosomes, resulting in a high localized concentration of the p5RHH and
subsequent endosomolysis 241. p5RHH-siRNA nanoparticles have been reported to
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effectively deliver their siRNA payloads to inflammatory macrophages in models of
arthritis 242–244. In addition, p5RHH-siRNA nanoparticles have been shown to
accumulate in areas of disrupted endothelium, such as tumors and atherosclerotic
plaques 245,246. Adaptation of the p5RHH nanoparticle system to deliver synthetic
mRNA could enable the development of mRNA therapeutics for these diseases.

In vivo distribution of Nanoparticles
In addition to the challenges faced in the uptake and endosomal escape
synthetic mRNA-loaded nanoparticles, targeting specific organs remains an unsolved
challenge. Furthermore, the short duration of expression from synthetic mRNA is
exacerbated to the rapid clearance of nanoparticles due to opsonization by serum
proteins. However, alterations in the composition of the nanoparticle surface and
composition begun to show improvements in these areas.

Adsorption of Serum Proteins
Initial studies with cationic LNP found that avidly bound by serum proteins,
primarily due to the strong positive surface charge of the LNP. This adsorption created a
protein corona around the LNP, increasing its diameter and imparting a negative
surface charge. The primary serum components responsible were identified as albumin,
high and low density lipoproteins (HDL, LDL), and macroglobulin 247. Similar
accumulation of serum proteins was also observed when using cationic polymeric
nanoparticles 248. The inclusion of PEGylated lipids or the use of PEG-copolymer blocks
was found to significantly reduce the amount of opsonization and extend the circulation

67

time of the nanoparticles and is now used in the majority of nanoparticle formulations
249,250

. As previously discussed, the binding of serum proteins to LNP was also reduced

by utilizing ionizable lipids 251.

Nanoparticle Clearance
The size of nanoparticles plays a large role in their clearance from the circulation.
The smallest nanoparticles, up to 5 nm in diameter, are removed from the blood by
glomerular filtration in the kidney. However, virtually any opsonization by serum proteins
will increase the effective diameter of the nanoparticle above this threshold and prevent
renal clearance 252. Larger particles are instead removed from circulation by uptake and
degradation in the liver.

Organ Sequestration
Given the relatively large size of LNP and polymeric nanoparticles, accumulation
of particles is typically observed almost exclusively in the liver after systemic
administration 167. The accumulated nanoparticles are avidly endocytosed by
hepatocytes due to opsonization by apolipoprotein E (ApoE) 253. Because of the
preferential uptake in the liver, most applications for systemically administered nucleic
acid therapies either target liver-specific disorders, as in the case of siRNA, or utilize the
liver as a biosynthetic depot. In addition, the accumulation of a protein corona on the
surface of non-PEGylated nanoparticles significantly increases their uptake by cells of
the mononuclear phagocyte system (MPS) 254.
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Alteration of the components used to build LNP or polymeric nanoparticles can
confer a degree of tissue specificity. For example, one group demonstrated a ionizable
LNP that resulted in nearly exclusive expression of the payload luciferase mRNA in the
immune cells of the spleen despite over a 10-fold higher uptake of particles by the liver
255

. Another group has developed a LNP that preferentially expressed luciferase in the

lungs 256. Further development of these nanoparticle systems may involve the addition
of targeting moieties to the surface of the nanoparticles, a strategy that has been
demonstrated for siRNA-loaded polymeric nanoparticles 257.

Nanoparticle-associated Toxicity
For clinical applications, the safety and toxicity of nanoparticles and their
components must be carefully examined. The cationic lipids commonly employed in
early LNP were found to produce unacceptable levels of immunogenicity and
hepatotoxicity due to induction of inflammatory cytokines and activation of TLR 258–260.
However, the switch to ionizable lipid formulations has virtually eliminated these
associated toxicities 261. The PEG-shielding commonly used in nanoparticles may prove
to be a double-edged sword as anti-PEG antibodies have been detected in over 20% of
blood samples without prior exposure to PEGylated drugs 262. These antibodies can
significantly accelerate the clearance of PEGylated nanoparticles, reduce their
efficiency, and potentially lead to adverse immune responses due to activation of the
complement system 263,264.
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Gap in Knowledge and Purpose of this Dissertation
Synthetic mRNA as a therapeutic modality has been greatly advanced in recent
years. The discovery of modified nucleotides, in particular, has reignited interest in the
use of synthetic mRNA over other gene vectors due to the reduction of innate
immunogenicity. The incorporation of target sites for endogenous regulators, such as
miRNA, and the rational design of gene circuits hold great promise for enabling tissue-,
cell-, or even environmental-responsive therapeutics. However, changes in the
efficiency of these regulatory elements due to incorporation of modified nucleotides,
which have been shown to alter mRNA structure and decoding, have not been
examined. To address this gap in knowledge, we transcribed synthetic miRNA-switches
with a variety of commonly used modified nucleotides. We examined the effects of the
nucleotides on the regulation of translation by various species of miRNA. In addition, we
also investigated the effect of sequence context and target site complementarity. We
found that these modified nucleotides can indeed reduce the silencing of transcripts by
miRNA, but this loss of regulation can be ameliorated by placing the miRNA target site
in the 5’ UTR of the transcript.
The delivery of synthetic mRNA remains the largest barrier to the widespread
application of this promising technology. Due to the sensitivity of mRNA to degradation
by extracellular nucleases, synthetic mRNA must be packaged in protective
nanoparticles. The size and charge of these nanoparticles drives their accumulation in
the liver and uptake by cells of the mononuclear phagocyte system. While uptake by
these cells can be avoided by minimizing the adsorption of serum proteins, delivering
synthetic mRNA to other organs has proven challenging. Entrapment of mRNA-loaded
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nanoparticles in the endosome after uptake also reduces the potency of mRNA
therapeutics. Despite the rapid advancement of mRNA therapeutics, further work is
necessary to overcome the remaining challenges to widespread clinical applications.
While altering the constituents of the commonly used LNP and polymeric nanoparticles
has yielded some improvements, investigation of novel mRNA delivery platforms is
lacking. We investigated a small cell-penetrating peptide, called p5RHH, that has a
cationic tail and is capable of spontaneously forming transfective nanoparticles with
mRNA. We showed that these nanoparticles are avidly endocytosed by cells, and that
the endosomal release of the payload mRNA is highly efficient. We also demonstrated
that these nanoparticles exhibit a high degree of RNase resistance and minimal
cytotoxicity. Finally, we found that systemic administration of these nanoparticles led to
robust expression of a fluorescent reporter in atherosclerotic plaques of ApoE-/- mice,
but produced no detectable expression in liver, spleen, lungs, or kidneys.
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Chapter 4
Materials and Methods
Ethical Approvals
All animal experiments were approved by the IACUC of the University of South
Florida (protocol #4197).

Cell Culture
B16F10 (ATCC CRL-6475), AD-HEK293 (Stratagene #240085), and HeLa
(ATCC CCL-2) cells were cultured in DMEM with 10% FBS. HUVEC and VSMC (Lonza)
were cultured in EGM-2 Endothelial Cell Growth Media or SMGM-2 Smooth Muscle Cell
Growth Media (Lonza), respectively. All cells were maintained in sub-confluent densities
to allow cell division throughout the course of the experiments. Experiments using
HUVEC and VSMC were carried out in cells between 3 to 7 passages.

mRNA Template Construction
Green fluorescent protein (GFP) constructs for the generation of in vitro
transcription were designed using the pLL3.7 plasmid, a gift from Luk Parijs (Addgene
plasmid # 11795). The 3’-UTR of human β-globin (132 bp) was amplified using HeLa
genomic DNA as template with forward and reverse primer oligonucleotides #1 and #2
(Table 4.1). The β-globin 3’-UTR PCR product and the pLL3.7 plasmid were then EcoRI
digested and ligated together to complete the construct. BamHI, PacI, and SphI

72

restriction sites were included upstream of the β-globin 3’-UTR in oligonucleotide #1 to
facilitate the insertion of miRNA target sites at the 3' UTR.
To construct GFP miRNA switches with one or two copies of the fully
complementary target sites for miR-126-3p (GFP-1x126TS or GFP-2x-126TS), we
annealed oligonucleotides #3-4 or oligonucleotides #5-6, respectively, and ligated them
into the plasmid using the BamHI restriction site added to the GFP 3’-UTR (Table 4.1).
To construct GFP with three or four copies of the fully complementary target sites for
miR-126-3p (GFP-3x126TS or GFP-4x126TS) at the 3'-UTR, we annealed
oligonucleotides #7-8, containing two copies of miR-126-3p fully complementary target
sites, and ligated them into the GFP-1x126TS or GFP-2x126TS plasmids using the PacI
restriction site (Table 4.1). Likewise, to construct GFP with two miR-126-3p seed target
sites (GFP-2x126seed) at the 3'-UTR, we annealed oligonucleotides #9-10 that
contained two copies of regions complementary to the seed sequence of miR-126-3p
and introduced them into the GFP plasmid using the BamHI restriction site. The same
strategy was used to construct GFP-4x21TS, GFP-4x145TS and GFP-4x122TS
plasmids by inserting four target sites for miR-21-5p (oligonucleotides #11-14), miR145-5p (oligonucleotides #15-18) or miR-122-5p (oligonucleotides #19-22) respectively,
using the BamHI and PacI sites (Table 4.1).
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Table 4.1. List of oligonucleotides used to generate plasmids and templates for in
vitro transcription of synthetic mRNA.
Construction of plasmids
1

EcoRI-BamHI-PacI-SphIβglobin 3'UTR

Forward

5’-ATTA-gaattc-ggatcc-ttaattaa-gcatgc-GCTCGCT
TTCTTGCTGTCCAATTTCTA
5’-ATTA-gaattc-GCAATGAAAATAAATGTTTTTTA
TTAGGCAGAATCCAGAT

2

EcoRI-βglobin 3'UTR

Reverse

3

BamHI-1x126TS-BamHI

Forward

5’-gatcc-CGCATTATTACTCACGGTACGA-g

4

BamHI-1x126TS-BamHI

Reverse

5’-gatcc-TCGTACCGTGAGTAATAATGCG-g

5

BamHI-2x126TS-BamHI

Forward

6

BamHI-2x126TS-BamHI

Reverse

7

PacI-2x126TS-PacI

Forward

8

PacI-2x126TS-PacI

Reverse

9

BamHI-2x126seed-BamHI

Forward

10

BamHI-2x126seed-BamHI

Reverse

11

BamHI-2x21TS-BamHI

Forward

12

BamHI-2x21TS-BamHI

Reverse

13

PacI-2x21TS-PacI

Forward

14

PacI-2x21TS-PacI

Reverse

15

BamHI-2x145TS-BamHI

Forward

16

BamHI-2x145TS-BamHI

Reverse

17

PacI-2x145TS-PacI

Forward

18

PacI-2x145TS-PacI

Reverse

19

BamHI-2x122TS-BamHI

Forward

20

BamHI-2x122TS-BamHI

Reverse

21

PacI-2x122TS-PacI

Forward

5’-gatcc-CGCATTATTACTCACGGTACGAGATC
GATCCGCATTATTACTCACGGTACGA-g
5’-gatcc-TCGTACCGTGAGTAATAATGCGGATC
GATCTCGTACCGTGAGTAATAATGCG-g
5’-taa-CGCATTATTACTCACGGTACGAGATCGA
TCCGCATTATTACTCACGGTACGA-ttaat
5’-taa-TCGTACCGTGAGTAATAATGCGGATCGA
TCTCGTACCGTGAGTAATAATGCG-ttaat
5’-gatccTTTAACTAAATGTAAGGTACGAATTTAT
TTAACTAAATGTAAGGTACGAA-g
5’-gatcc-TTCGTACCTTACATTTAGTTAAATAAA
TTCGTACCTTACATTTAGTTAAA-g
5’-gatcc-TCAACATCAGTCTGATAAGCTAgatcgat
cTCAACATCAGTCTGATAAGCTA-g
5’-gatcc-TAGCTTATCAGACTGATGTTGAgatcgat
cTAGCTTATCAGACTGATGTTGA-g
5’-taa-TCAACATCAGTCTGATAAGCTAgatcgatcT
CAACATCAGTCTGATAAGCTA-ttaat
5’-taa-TAGCTTATCAGACTGATGTTGAgatcgatcT
AGCTTATCAGACTGATGTTGA-ttaat
5’-gatcc-AGGGATTCCTGGGAAAACTGGACgatc
gatcAGGGATTCCTGGGAAAACTGGAC-g
5’-gatcc-GTCCAGTTTTCCCAGGAATCCCTgatcg
atcGTCCAGTTTTCCCAGGAATCCCT-g
5’-taa-AGGGATTCCTGGGAAAACTGGACgatcgat
cAGGGATTCCTGGGAAAACTGGAC-ttaat
5’-taa-GTCCAGTTTTCCCAGGAATCCCTgatcgatc
GTCCAGTTTTCCCAGGAATCCCT-ttaat
5-gatcc-CAAACACCATTGTCACACTCCAgatcgatc
CAAACACCATTGTCACACTCCA-g
5’-gatcc-TGGAGTGTGACAATGGTGTTTGgatcgat
cTGGAGTGTGACAATGGTGTTTG-g
5’-taa-CAAACACCATTGTCACACTCCAgatcgatcC
AAACACCATTGTCACACTCCA-ttaat
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Table 4.1 (Continued)
22

PacI-2x122TS-PacI

Reverse

23

XbaI-βglobin 3'UTR

Forward

24

XbaI-βglobin 3'UTR

Reverse

25

NheI-Luc

Forward

26

BamHI-Luc

Reverse

27

NotI-βglobin 3’UTR

Reverse

5’-taa-TGGAGTGTGACAATGGTGTTTGgatcgatc
TGGAGTGTGACAATGGTGTTTG-ttaat
5’-tagaat-TCTAGA-GCTCGCTTTCTTGCTG
TCCAATTTCTA
5’-tagaat-TCTAGA-GCAATGAAAATAAATGT
TTTTTATTAGGCAGAATCCAGAT
5’-atcc-GCTAGC-ACCATGGAAGACGCCAAAA
ACATA
5’-ttaa-GGATCCGAATTACAATTTGGACTTTC
CGCC
5’-tagaat-GCGGCCGC-GCAATGAAAATAAATG
TTTTTTATTAGGCAGAATCCAGAT

Templates for in vitro transcription
28

29

T7-βglobin 5' UTR-GFP

T7-βglobin 5'UTR-niRFP

Forward

5’-CTTATGTCAATAATACGACTCACTATAGGGACATTTGCTTCTGACACAACTGTGTTCACTAGC
AACCTCAAACAGACCACC-ATGGTGAGCAAGG
GCGAGGAGCTGTT

Forward

5’-cttatgtcaa-TAATACGACTCACTATAGGGACATTTGCTTCTGACACAACTGTGTTCACTAGC
AACCTCAAACAGACCACC-ATGGCGCGTAAGG
TCGATCTCA

30

T7-βglobin 5'UTR-Luc

Forward

5’-cttatgtcaa-TAATACGACTCACTATAGGGACATTTGCTTCTGACACAACTGTGTTCACTAGC
AACCTCAAACAGACCACC-ATGGAAGA
TGCCAAAAACATTAAGAAGGGCCCAGCG

31

βglobin 3’UTR

Reverse

5’-GCAATGAAAATAAATGTTTTTTATTAGGCAG
AATCCAGAT

32

T7-βglobin 5’UTR-1x126TSGFP

Forward

5’-CTTATGTCAATAATACGACTCACTATAGGGACATTTGCTTCTGACACAACTGTGTTCACTAGC
AACCTCAAACAGACCACC-CGCATTATTACTCA
CGGTACGA-ctagcgctaccggtcgccacc-ATGGTGA
GCAAGGGCGAGGAGCTGTT
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Near infrared fluorescent protein 670 (niRFP) constructs were constructed in a
similar manner using forward and reverse primer oligionucleotides #23 and #24 to clone
the β-globin 3’-UTR from HeLa genomic DNA, followed by XbaI digestion and ligation of
the PCR product and the piRFP-N plasmid, a gift from Vladislav Verkhusha (Addgene
plasmid # 45457) (Table 4.1). Firefly Luciferase (Luc) constructs were created by
cloning the luciferase coding sequence out of pGL2 Basic (Promega) using forward and
reverse primer oligonucleotides #25 and #26 (Table 4.1). The Luc PCR product and the
pLL3.7 plasmid with the β-globin 3’-UTR were digested with NheI and BamHI, removing
GFP from the pLL3.7 plasmid. The Luc coding sequences was then ligated into the
pLL3.7 to form the final construct. The β-globin 3’-UTR was added to the 3’ end of GFP
in pT7-VEE-GFP, a gift from Steven Dowdy (Addgene plasmid #58977), after PCR with
primers #23 and #27 by double digestion with XbaI and NotI (Table 4.1).

in vitro Transcription
For in vitro transcription, templates were generated by PCR using forward
primers #28, #29, or #30 (containing a T7 promoter, 5’-UTR of human β-globin and the
first ~20 bases of GFP, niRFP or Luc, respectively) and reverse primer #31 (starting at
the end of the human β-globin 3’-UTR) (Table 4.1). Templates for the GFP miRNA
switch with the miR-126-3p target in the 5’ UTR were generated by using forward primer
#32 and reverse primer #31 (Table 4.1). VEE-GFP template was generated by
linearizing the pT7-VEE-GFP-βglobin plasmid with MluI.
In vitro transcription was performed, per the manufacturer’s protocol, using the
HiScribe T7 High Yield RNA synthesis kit (NEB) followed by ammonium acetate
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precipitation as previously described.52 Pseudouridine-5'-Triphosphate (TriLink
Biotechnologies, N-1019), 5-Methylcytidine-5'-Triphosphate (TriLink Biotechnologies, N1014), N1-methylpseudouridine-5’-Triphosphate (TriLink Biotechnologies, N-1081), and
2-Thiouridine-5’-Triphosphate (TriLink Biotechnologies, N-1032) were substituted during
IVT to generate modified mRNA. The RNA was then capped using the ScriptCap™ m7G
Capping System (CellScript) and tailed using the A-Plus™ Poly(A) Polymerase Tailing
Kit (CellScript). The addition of >100 nt poly(A) tail was confirmed by electrophoresis on
a 1% agarose gel. Following poly(A)-tailing, the mRNA was precipitated using 1x
volume of 5M ammonium acetate, re-suspended in DNase/RNase-free water, quantified
by spectrophotometry, and stored at -80 ˚C until use.

Preparation of p5RHH
p5RHH peptides were synthesized by Genscript (Piscataway, NJ, USA),
dissolved at 5 mM in DNase/RNase-free water, and stored at -80 ˚C until use.

Formation and characterization of p5RHH-mRNA nanoparticles
The synthetic mRNA and p5RHH peptides were diluted to 70 ng/µL and 400 µM,
respectively, in DNase/RNase-free water. The mRNA and p5RHH were then combined
at a 1:1 volume ratio in 8 volumes of OptiMEM (Gibco) and mixed briefly. The solution
was incubated at 37 ˚C for 40 minutes prior to use. To visualize p5RHH and mRNA
binding a gel shift assay was performed on Cy5-labeled GFP mRNA complexed with
increasing amounts of p5RHH. The resulting products were visualized by gel
electrophoresis on an RNase-free 1% agarose gel.
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To determine the size of the p5RHH-mRNA nanoparticles, a 30 µL volume of
p5RHH-mRNA nanoparticle solution was pipetted onto a 200 nm polycarbonate track
etched membrane, air dried, sputter coated with gold/palladium, and imaged using a
JSM6490 Scanning Electron Microscope (JEOL).

mRNA and miRNA mimic Transfection
Cells were plated in 24-well plates (AD-HEK293, HeLa, VSMC: 5x104/well;
HUVEC: 1x105/well) on the day prior to the transfection with miRIDIAN miRNA mimics
(GE Dharmacon), miRNA mimics were transfected at a final concentration of 200nM
using DharmaFECT #4 Transfection Reagent (Dharmacon). Lipofectamine® 2000
(Thermo Fisher Scientific) was used for mRNA transfections. Media was changed after
four hours to remove transfection reagent from HUVEC, VSMC, and HeLa cells. Cells
were collected 24 hours following mRNA transfection.
Cells were plated in 48-well plates at 15,000 cells/well on the day prior to
transfection with the p5RHH-mRNA nanoparticles. Cells were transfected by replacing
the cell culture medium with the p5RHH-mRNA nanoparticle solution supplemented with
fresh culture medium to a final volume of 100 µL per well. Bafilomycin [1 µM] and
chloroquine [50 µM] were added to the transfection media prior to addition to the wells.
For RNase protection assays 350 ng of GFP mRNA was complexed with 2.0
nmol of p5RHH prior to addition 0.25 µg RNaseA or vehicle control to the nanoparticle
mixture and incubation at 37 ˚C for 20 minutes. An equal amount of uncomplexed GFP
mRNA was also subjected to RNaseA treatment before nanoparticle formation. The
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resulting products were added to B16F10 cells, and the percent of GFP positive cells
were determined by flow cytometry after 24 hours.

Flow Cytometry
Prior to analysis by flow cytometry, cells were trypsinized, washed and
resuspended with PBS. p5RHH-mRNA nanoparticle uptake and transfection efficiency
were determined using a FACSCanto II (BD Bioscience). To assess cytotoxicity,
propidium iodide was added to the resuspended cells 1 minute prior to analysis.

Western Blotting
Total protein lysates were fractionated by SDS-PAGE as previously described
265

, transferred to nitrocellulose membranes, and blocked with Odyssey blocking buffer

for 1 hour at room temperature. Membranes were probed overnight with rabbit anti-GFP
(Invitrogen A-6455, 1:1000) and rabbit anti-α-tubulin (Cell Signaling Technology #2144)
or rabbit anti-GFP (Life Technologies A-6455, 1:1000) primary antibodies followed by
donkey anti-rabbit IgG IRDye680 (LI-COR 926-68073, 1:5000) secondary antibody.
Blots were imaged using the Odyssey Infrared Imaging System (LI-COR) and quantified
using Image Studio software (LI-COR). GFP expression was normalized to GAPDH or
α-tubulin, which was used as a loading control.

Luciferase Assay
Luciferase activity was measured 24 hours after transfection with p5RHH-LUCmRNA. Cells were rinsed with PBS prior to lysis with Cell Culture Lysis Reagent
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(Promega E1531). Luminescence was measured using a Cytation 3 plate reader
(BioTEK) using luciferase assay substrate (Promega E1500) per the manufacturer’s
protocol.

miRNA isolation and RT-qPCR
Total cellular RNA was isolated from cultured cells using miRNeasy mini kit
(QIAGEN) according to the manufacturer’s protocol and stored at -80˚C in RNase-free
water. Reverse transcription was performed on 50ng of total RNA using TaqMan
MicroRNA Reverse Transcription Kit (Applied Biosystems) and olidgo-d(T) or miRNAspecific RT primers (Thermo Fisher Scientific). qPCR was performed using TaqMan
MicroRNA Assays (Thermo Fisher Scientific) for 40 cycles on a QuantStudio 3 (Applied
Biosystems). Relative expression of miRNAs and mRNA was calculated in comparison
to the snoRNA U18 or endogenous GAPDH, respectively, using the 2-∆Ct method.

Cytotoxicity Assay
Cytotoxicity was analyzed 24 hours after transfection of miRNA switches by
adding propidium iodide (PI) directly to wells without removing the culture media. PI was
added to the transfected wells to a final concentration of 4 µM. Fluorescence
microscopy images were captured after a 30-minute incubation. The number of dead
cells was calculated from 4 fields per well using ImageJ.
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ApoE-/- Mouse Model of Atherosclerosis
Male ApoE-/- mice were obtained from Jackson Laboratory (Bar Harbor, ME,
USA) and housed in the USF Health Comparative Medicine Vivarium on a 12-hour
light/dark cycle with ad libitium access to food and water. Animals were placed on a
high fat diet (60% kcal from fat) for 18 months prior to use in these experiments.
Animals were anesthetized by isoflurane inhalation prior to administration of 200 µl
p5RHH-niRFP nanoparticles or vehicle (Optimem) by retro-orbital injection. The animals
were sacrificed 48 hours after nanoparticle injection.

Tissue Distribution Analysis
ApoE-/- mouse organs collected for histological analysis were fixed overnight in
4% PFA followed by an overnight immersion in a cryprotective 30% sucrose solution as
previously described 142. The organs were then mounted in OCT compound and
cryosectioned at 20 µm thickness. Sections were then dried for one hour prior to
addition of Prolong Antifade Mountant with DAPI (ThermoFisher). Tissue sections were
then examined by fluorescence confocal microscopy for DAPI and niRFP using an
Olympus FluoView FV1200. Tissues collected for mRNA analysis were snap frozen
after collection and stored in liquid nitrogen until used. Tissues were homogenzied and
total RNA was extracted using RNeasy Mini Kit (Qiagen). cDNA was prepared by using
oligo-d(t) (NEB) and M-MulV reverse transcriptase (NEB). niRFP transcript level was
assayed by SYBR RT-PCR using primers #33 and #34 (Table 4.2). GAPDH, measured
using primers #35 and #36 (Table 4.2), was used as a loading control.
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Table 4.2 Primers for SYBR RT-PCR.
Primers for SYBR RT-PCR
33
34
35
36

niRFP
niRFP
GAPDH
GAPDH

Forward
Reverse
Forward
Reverse

5’- AAGTCGCTCGAAGAGATGGC
5’- GAAGCGGTACAACATCACGC
5’-GTGTTCCTACCCCCAATGTGT
5’-ATTGTCATACCAGGAAATGAGCTT

Male C57BL6/J were obtained from Jackson Laboratory (Bar Harbor, ME, USA)
and housed in the USF Health Comparative Medicine Vivarium on a 12-hour light/dark
cycle with ad libitium access to food and water. Animals were injected intravenously
with 200 µL p5RHH-GFP nanoparticles and sacrificed 48 hours later. Tissues collected
for protein expression analysis were snap frozen after collection and stored in liquid
nitrogen until analysis by Western blotting.

Statistics
Data was analyzed using two-tailed Student’s t-test with Holm-Sidak correction,
one-way ANOVA with Tukey’s post-hoc test or two-way ANOVA with Tukey’s post-hoc
test using GraphPad Prism 7.0 software. p < 0.05 was considered statistically
significant. All data are reported as mean ± standard error of the mean (SEM) of at least
3 independent experiments unless stated otherwise.
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Chapter 5
Nucleotide modification alters microRNA-dependent silencing of microRNA
switches
Note to the Reader
Portions of this chapter have been previously published in Molecular Therapy –
Nucleic Acids, 14: 339-350 and have been reproduced here under Creative Commons
license CC BY-NC-ND 4.0.
This work was produced in collaboration with Dr. John Canfield, Dr. Ezinne
Francess Mong, Jeffrey VanWye, and Dr. Hana Totary-Jain. J.L., J.V., and H.T.-J.
designed the research, performed the experiments, and analyzed the data. J.C. and
E.F.M. performed experiments and edited the paper. J.L. and H.T.-J. prepared figures
and wrote the paper.

Introduction
mRNA therapeutics are becoming valuable tools for the treatment of a broad
range of human diseases 86. Many preclinical and clinical trials are underway using in
vitro transcribed (IVT) mRNAs as cancer treatments 266, vaccines 171, and protein
replacement therapies 167,267. mRNA-based therapies represent a remarkable
alternative to DNA-based therapies, with a wide range of advantages, including i)
increased safety: their non-replicative nature carries no risk for integration into the host
genome thus eliminating the chances of genomic alteration; ii) broader applications:
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exogenous mRNAs preclude the need for nuclear localization and allows rapid protein
expression in any cell type, including non-dividing cells; iii) streamlined production: cellfree systems enable reproducible, rapid, and cost-effective synthesis with stringent
quality control. The inclusion of structural elements such as a 5'-cap, 5'- and 3'-UTRs,
and a polyA tail has been shown to significantly improve the stability and translational
efficiency of IVT mRNA.1 Additionally, codon engineering and incorporation of
chemically modified nucleotides that mimic the naturally occurring intracellular
modifications have been shown to reduce immunogenicity and increase translation of
IVT mRNA 105,268.
To date, 171 types of modified bases have been described, although most types
are thought to be rare.8 Post-transcriptional modifications of RNA are frequent,
conserved across species, and observed in different RNA classes. These modifications
distinguish endogenous RNA molecules from invading viral or microbial RNA molecules.
Pseudouridine (Ψ) is one of the most common nucleotide modification in cellular RNA
and is produced by the irreversible isomerization of uridine to Ψ 269–271. Hundreds of
pseudouridylation sites have been identified in eukaryotic mRNA and have been shown
to be dynamically modulated in response to environmental changes and stresses 270–273.
Ψ affects the stability of endogenous mRNA, indicating potential regulatory roles in
mRNA metabolism 270,271. Incorporating Ψ into IVT mRNA has been shown to increase
translation and decrease immunogenicity 85,102,104,105,108. The benefits of incorporating Ψ
in IVT mRNA are enhanced when Ψ is combined with other natural modified
nucleotides, such as 5-methylcytidine (m5C) 179,274. Other modifications, such as N1methylpseudourdine (m1Ψ) have recently been shown to further improve translation
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and evasion of the innate immune system 103,106. These insights have made IVT mRNA
a viable therapeutic option. However, safe and effective mRNA therapeutics require
cell-specific targeting to maximize the benefits and minimize off-target effects.
Cell-specific expression has been achieved using various strategies including the
incorporation of ligand-sensing aptamers 146 or target sites for endogenous miRNA
275,276

. The addition of artificial miRNA target sites into the 3’-UTR of the transgene

expression vector allows for targeting by the RNA Induced Silencing Complex (RISC)
and leads to the silencing of the transgene in cells expressing the corresponding
miRNA. We have previously employed this strategy using an adenoviral vector with
target sites for miR-126-3p, an endothelial cell specific miRNA, to selectively inhibit the
proliferation of arterial vascular smooth muscle cells (VSMC) and prevent restenosis
while allowing re-endothelialization of the vessels after balloon injury in a rat carotid
artery 142. Recently, IVT mRNAs that contain artificial miRNA target sites, called miRNA
switches, were successfully used to achieve cell-specific expression of synthetic
circuits, identify and eliminate undifferentiated induced stem cells, and achieve cellselective genome editing using miRNA-responsive CRISPR-Cas9 143,144,158,277.
The intricate mechanisms of miRNA-mediated silencing have been the focus of
extensive investigations. However, to date, the relative contributions of mRNA decay
and translational repression to the overall silencing remain under debate. Moreover, the
influence of chemically modified nucleotides on miRNA-dependent mRNA silencing has
not been investigated. Since nucleotide modifications increase translation and stabilize
the 2D and 3D RNA structures, thereby altering interactions within the RNA itself and
with RNA-binding proteins 278, we sought to determine whether nucleotide modifications
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affect the regulation of miRNA switches. In this work we compared the effect of
nucleotide modifications (Ψ, Ψ/m5C and m1Ψ) on the performance of different miRNA
switches in different cell types. We also tested the effect of the location and the
complementarity of the miRNA target sites in the miRNA switches.

Results
Nucleotide modifications alter miRNA-dependent silencing of miRNA switches
To create reporter miRNA switches, we introduced one to four copies of a 22-nt
sequence fully complementary to the mature miR-126-3p at the 3’ end of IVT GFP
mRNA (GFP-1x126TS, GFP-2x126TS, GFP-3x126TS, GFP-4x126TS). We used AdHEK293 cells, since they display minimal cytotoxicity following transfection with
unmodified IVT mRNA due to the lack of expression of almost all Toll-like receptors
(TLRs) 102,103,279. Since Ad-HEK293 cells express very low levels of miR-126-3p
compared to human umbilical vein endothelial cells (HUVEC) (Figure 5.1 A), we used
exogenous mimics to overexpress miR-126-3p in Ad-HEK293. To determine the optimal
time needed for the loading of the miR-126-3p mimics into the RISC, Ad-HEK293 cells
were transfected with miR-126-3p mimics simultaneously or 4, 8 or 24 hours prior to
transfection with unmodified GFP-4x126TS miRNA switches. miR-126-3p mimics
reduced GFP expression to < 37% (p < 0.05) at all time points compared to vehicle
control, and the lowest GFP expression (16.3%) was seen in cells transfected with miR126-3p mimics 24 hours prior to the GFP-4x126TS miRNA switches (Figure 5.1 B).
Therefore, in all subsequent experiments involving Ad-HEK293 cells, we transfected
miRNA mimics 24 hours prior to the miRNA switch transfection.
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To establish the baseline for miRNA switch silencing, we first assessed GFP
expression in Ad-HEK293 cells transfected with unmodified (0% Ψ) GFP mRNA
containing zero to four copies of miR-126-3p fully complementary target sites at the
3'UTR in the presence of miR-126-3p mimics, miR-143-3p mimics or vehicle control. In
cells transfected with unmodified GFP-1x126TS mRNA, miR-126-3p mimics reduced
GFP protein levels to 23.5% (p < 0.05) of vehicle control (Figure 5.2 A and B).
Increasing the number of miR-126-3p target sites from one to four decreased the
expression of GFP protein levels from 23.5% to 6.8% in the presence of miR-126-3p
mimics, whereas miR-143-3p mimics showed no difference in GFP expression (Figure
5.2 A and B).
We then synthesized GFP mRNA with 25%, 50%, or 100% substitution of uridine
for Ψ. Transfection of these Ψ-modified mRNAs into Ad-HEK293 cells showed >2-fold
increase (p < 0.05) in GFP expression with 50% and 100% Ψ compared to unmodified
(0% Ψ) GFP mRNA (Figure 5.3). We found that increasing Ψ substitutions, from 0% to
100%, reduced miR-126-3p dependent silencing of GFP-1x126TS from 23.5% to 36.4%
relative GFP expression (Figure 5.2 A and B). Increasing the number of miR-126-3p
target sites from one to four further decreased the expression of GFP protein levels to <
13% at all percentages of Ψ-substitution in the presence of miR-126-3p but not miR143-3p (Figure 5.2 A and B). The increased silencing of GFP-4x126TS switches
compared to GFP-1x126TS was seen at all levels of Ψ substitution, but only reached
statistical significance in the 100% Ψ-modified miRNA switches (p < 0.05).
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Figure 5.1. Expression of miR-126-3p and optimization of miRNA mimic delivery
in Ad-HEK293 cells.
(A) Real-time PCR analysis of the indicated miRNA expression in Ad-HEK293 and
HUVEC. (B) Representative immunoblot and densitometric quantification of Ad-HEK293
cells transfected with miR-126-3p mimics or vehicle control at the indicated time point
before transfection with unmodified GFP-4x126TS miRNA switches. GFP and GAPDH
expression were measured after 24 hours. Data represent the mean ± SEM of three
independent experiments, normalized against U18 (A) or GAPDH (B) and relative to AdHEK293 cells (A) or vehicle control (B). *p < 0.05 versus Ad-HEK293 (A) or 0 hour time
point (B). Numbers above bars indicate the mean values.
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Figure 5.2. Increasing the number of miRNA-target sites at the 3'UTR of the
miRNA switches counteracts the impact of the Ψ-substitution.
(A-D) Representative GFP and GAPDH immunoblots (A and C) and densitometric
quantification (B and D) of Ad-HEK293 cells transfected with miR-126-3p, miR-134-3p
mimics or vehicle, 24 hours before transfection with the indicated GFP miRNA switch (A
and B) or HUVECs transfected with the indicated 100% Ψ-modified GFP miRNA
switches (C and D). GFP and GAPDH expression were measured after 24 hours. Data
represent the mean ± SEM, normalized against GAPDH (B and D) and relative to
vehicle controls (B) or untargeted GFP control (D). *p < 0.05 versus miR-143 control
(B); versus GFP treated cells (D). #p < 0.05 for the indicated comparisons. “#TS”
indicates the number of miR-126-3p target sites in the 3’UTR of the miRNA switch.
“NTC” indicates non-transfected control. Numbers above bars indicate the mean values.
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Figure 5.3. Ψ-substitution increases GFP expression from IVT mRNA.
(A-B) Representative immunoblot (A) and densitometric quantification (B) of AdHEK293 cells transfected with GFP-encoding IVT mRNA with the indicated percentage
of Ψ-substitution. GFP and GAPDH expression were measured after 24 hours. Data
represent the mean ± SEM of three independent experiments, normalized against
GAPDH and relative to unmodified GFP-encoding IVT mRNA. *p < 0.05 versus
unmodified GFP-encoding IVT mRNA. Numbers above bars indicate the mean values.
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We also assessed the ability of the endogenous miR-126-3p to silence
unmodified (0% Ψ) or 100% Ψ-modified GFP miRNA switches containing zero to four
copies of miR-126-3p fully complementary target sites at the 3'UTR. HUVECs
transfected with unmodified GFP mRNA displayed minimal GFP expression and 3.4-fold
(p < 0.05) increase in the number of dead cells compared to non-transfected controls
(Figure 5.4 A and B). However, HUVECs transfected with 100% Ψ-modified GFP
mRNA displayed increased GFP expression and no difference in the number of dead
cells compare to non-transfected controls (Figure 5.4 A and B). Similar to Ad-HEK293
cells transfected with miR-126-3p mimics, HUVECs transfected with 100% Ψ-modified
GFP-1x126TS showed 42.3% GFP expression compared to 100% Ψ-modified GFP
mRNA (p < 0.05). Increasing the number of miR-126-3p target sites from one to four
further decreased the expression of GFP to 25.1% but did not reach statistical
significance (Figure 5.2 C and D).
To determine whether the reduction in GFP expression is due to transcript
cleavage or reduced translation we analysed GFP transcript levels of HUVECs 24 hours
after transfection with 100% Ψ-modified GFP-encoding miRNA switches with zero, one
or four fully complementary target sites for miR-126-3p in the 3’UTR. GFP-1x126TS
mRNA levels were reduced to 59.8% of cells transfected with 100% Ψ-modified GFP
mRNA. Increasing the number of miR-126-3p target sites to four did not further
decrease GFP mRNA levels (Figure 5.5), whereas GFP protein levels continued to
decrease with the additional target sites (Figure 5.2 C and D). These results show that
the additional fully complementary miRNA target sites do not increase the cleavage of
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miRNA switches but still contribute to the miRNA-mediated silencing by increasing
translational repression.
Lastly, we assessed sponging of the endogenous miRNA by miRNA switches.
HUVEC were transfected with 100% Ψ-modified GFP containing zero, one or four miR126-3p target sites at the 3'UTR, and after 24 hours the expression of miR-126-3p and
PIK3R2, a known miR-126-3p target, were determined by RT-PCR. We found that
inclusion of one or four miR-126-3p target sites reduced endogenous miR-126-3p levels
to ~ 55% (p < 0.05) and increased the mRNA level of PIK3R2 ~1.5-fold (p < 0.05). No
difference was observed in the sponging of miR-126-3p or PIK3R2 expression between
cells transfected with GFP-1x126TS and GFP-4x126TS (Figure 5.6 A and B). These
data indicate that miRNA switches that contain even one fully complementary miRNA
target site reduce the availability of the endogenous cognate miRNA and impact the
expression of its target genes.
Recent studies have used combinations of modified nucleotides to further
decrease the innate immune response to exogenous mRNA 179,274. We therefore tested
whether 100% substitution with both Ψ and m5C alters miRNA-dependent silencing of
GFP miRNA switches that contained zero to four miR-126-3p fully complementary
target sites at the 3'UTR. Ad-HEK293 cells transfected with 100% Ψ/m5C GFP1x126TS showed 18.4% GFP expression (p < 0.05), equivalent to unmodified GFP1x126TS miRNA switches (23.5%). Similar to unmodified and Ψ-modified miR-126-3p
switches, 100% Ψ/m5C-modified GFP-4x126TS produced 14.5% relative GFP
expression (p < 0.05) (Figure 5.7 A and B). However, unlike Ψ-modified miRNA
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switches, the silencing provided by one miR-126-3p target site in the Ψ/m5C-modified
miRNA switches was equal to the silencing of miRNA switches with four target sites.
When the 100% Ψ/m5C-modified GFP mRNA was tested in HUVECs, we
observed GFP expression and no difference in the number of dead cells compared to
non-transfected controls (Figure 5.4 A and B). HUVECs transfected with 100% Ψ/m5C
GFP-1x126TS showed 39.2% GFP expression compared to GFP mRNA controls. As
was observed in Ad-HEK293 cells, increasing the number of miR-126-3p target sites at
the 3’ UTR produced no increase in the silencing (Figure 5.7 C and D). These data
demonstrate that in Ψ/m5C-modified miR-126-3p switches, unlike unmodified or Ψmodified miR-126-3p switches, inclusion of just one miR-126-3p target site at the 3’
UTR achieved the same miRNA-dependent silencing as four target sites.
To further explore the influence of the modified nucleotides on the silencing of
miRNA switches, we designed GFP mRNA containing four fully complementary target
sites at the 3'UTR for miR-21-5p which contains six uridines and five cytosines, (GFP4x21TS), or miR-145-5p (GFP-4x145TS), which contains four uridines and four
cytosines. In contrast miR-126-3p contains six uridines and six cytosines (Figure 5.8
A). Ad-HEK293 cells were transfected with unmodified, 100% Ψ- or 100% Ψ/m5Cmodified GFP, GFP-4x21TS or GFP-4x145TS miRNA switches 24 hours after
transfection with miR-21-5p, miR-145-5p, miR-143-3p mimics or vehicle control. In cells
transfected with unmodified-, Ψ- or Ψ/m5C-modified GFP-4x21TS mRNA switches, only
miR-21-5p mimics reduced GFP protein levels to 10.5%, 41.5% and 25.6%, respectively
compared to vehicle control (p < 0.05), whereas miR-145-5p or miR-143-3p showed no
inhibitory effect (Figure 5.8 B and C).
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Figure 5.4. Nucleotide modification decreases cytotoxicity and increases GFP
expression in HUVEC.
(A-B) Representative fluorescence microscopy images (A) and number of dead cells
per field (B) of HUVEC 24 hours after transfection with GFP-encoding IVT mRNA with
the indicated modified nucleotides (Scale bars: 200 μm; 20x magnification). Media was
changed four hours after mRNA transfection. Fluorescence Imaging and quantification
of dead cells was performed by adding propidium iodide after 24 hours without removal
of the media. Data represent the mean ± SEM from four non-overlapping fields.
Numbers above bars indicate the mean values.
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Figure 5.5. Additional miRNA target sites do not increase cleavage of miRNA
switches.
Real Time-PCR analysis of GFP normalized to GAPDH mRNA from HUVEC transfected
with the indicated 100% Ψ-modified GFP miRNA switch. Data represent the mean ±
SEM of one representative experiment performed in triplicate. *p < 0.05 versus GFP
mRNA transfected cells. Numbers above bars indicate the mean values.

Figure 5.6. miRNA sponging by miRNA switches in HUVEC.
(A-B) Real Time-PCR analysis of miR-126-3p normalized to U18 snRNA (A) and
PIK3R2 normalized to GAPDH mRNA (B) from HUVEC transfected with the indicated
100% Ψ-modified GFP miRNA switch. Data represent the mean ± SEM of one
representative experiment performed in triplicate. *p < 0.05 versus GFP mRNA
transfected cells. Numbers above bars indicate the mean values.
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Figure 5.7. Ψ/m5C substitution prevents increased silencing by additional miR126-3p target sites.
(A-D) Representative GFP and GAPDH immunoblots (A and C) and densitometric
quantification (B and D) of Ad-HEK293 cells transfected with miR-126-3p, miR-143-3p
mimics or vehicle, 24 hours before transfection with the indicated GFP miRNA switch (A
and B) or HUVECs transfected with the indicated 100% Ψ/m5C-modified GFP miRNA
switches (C and D). GFP and GAPDH expression were measured after 24 hours. Data
represent the mean ± SEM, normalized against GAPDH and relative to vehicle control.
*p < 0.05 versus miR-143 control (B); versus GFP treated cells (D). #p < 0.05 for the
indicated comparisons. “#TS” indicates the number of miR-126-3p target sites in the
3’UTR of the miRNA switch. “NTC” indicates non-transfected control. Numbers above
bars indicate the mean values.
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Similarly, in cells transfected with unmodified-, Ψ- or Ψ/m5C-modified GFP-4x145TS
mRNA, only miR-145-5p mimics reduced GFP protein levels to 11.0%, 43.8% and
32.6%, respectively compared to vehicle control (p < 0.05), whereas miR-21-5p or miR143-3p showed no inhibitory effect (Figure 5.8 B and C). Although the silencing of Ψor Ψ/m5C-modified GFP-4x21TS and GFP-4x145TS by miR-21-5p and miR-145-5p
mimics, respectively, was less effective compared to unmodified miRNA switches it did
not reach statistical significance (Figure 5.8 B and C). We also designed GFP mRNA
containing four fully complementary target sites at the 3'UTR for miR-122-5p, which
contain 4 uridines and 9 cytosines, and found no difference in GFP silencing of
unmodified (9.5%), 100% Ψ- (11.6%) or 100 % Ψ/m5C-modified (20.2%) GFP-4x122TS
miRNA switch by miR-122-5p mimics (Figure 5.8 D and E). Taken together these data
indicate that, Ψ and Ψ/m5C-modification tend to decrease the silencing of the miRNA
switches in comparison to the unmodified miRNA switches.

Regulation of Ψ- and Ψ/m5C-modified miRNA switches is cell type-dependent
We also tested these miRNA switches in cell types that endogenously express the
cognate miRNAs to confirm the effects we observed using miRNA mimics in AdHEK293 cells. We used HUVEC and VSMC, which express high levels of miR-126-3p
and miR-145-5p, respectively in addition to miR-21-5p. We also used HeLa cells, which
express high levels of miR-21-5p, but neither miR-126-3p nor miR-145-5p (Figure 5.9
A).
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Figure 5.8. Silencing of Ψ- and Ψ/m5C-modified modified miRNA switches is
independent of the U or C content.
(A) Sequences of miR-126-3p, miR-21-5p, miR-145-5p, and miR-122-5p and their
complementary target sites. ^ denotes the site of Argonaute cleavage. Red bases are
complementary to the seed sequence. (B-E) Representative immunoblots (B and D)
and densitometric quantification (C and E) of Ad-HEK293 cells transfected with the
indicated miRNA mimics or vehicle control 24 hours before transfection with the
indicated miRNA switches. GFP and GAPDH expression were measured after 24 hours.
Data represent the mean ± SEM, normalized against GAPDH and relative to vehicle
control. *p < 0.05 versus miR-143 control. “NTC” indicates non-transfected control.
Numbers above bars indicate the mean values.
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HUVECs transfected with Ψ-modified or Ψ/m5C-modified GFP-4x126TS
switches showed a similar reduction in GFP expression, to 42.3% or 30.4%
respectively, compared to their respective GFP mRNA transfected controls (p < 0.05).
However, Ψ-modified GFP-4x21TS miRNA switches reduced GFP expression to 55.2%
of Ψ-modified GFP transfected cells (p < 0.05), while Ψ/m5C-modified GFP-4x21TS
expression was reduced to only 70.5% of Ψ/m5C-modified GFP transfected controls,
which did not reach statistical significance. Lastly, HUVECs transfected with Ψ- or
Ψ/m5C-modified GFP-4x145TS showed no decrease in GFP expression compared to
GFP controls (Figure 5.9 B and C).
In VSMC, transfection of either Ψ- or Ψ/m5C modified GFP-4x126TS switches
did not decrease GFP expression compared to Ψ- or Ψ/m5C modified GFP mRNA
controls. Ψ-modified GFP-4x21TS switches produced 20.8% GFP expression relative to
Ψ-modified GFP mRNA controls (p < 0.05), while Ψ/m5C-modification exhibited 73.0%
GFP expression relative to the Ψ/m5C-modified GFP mRNA control. Interestingly, Ψmodified GFP-4x145TS switches exhibited very little silencing (74.2% relative GFP
expression, p > 0.05) compared to the Ψ-modified GFP mRNA transfected controls and
Ψ/5mC-modified GFP-4x145TS switches showed no silencing at all (Figure 5.9 D and
E). No statistically significant differences in GFP expression were observed in the
Ψ/5mC-modifed GFP-4x21TS and GFP-4x145TS compared to the Ψ-modified switches.
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Figure 5.9. Silencing of Ψ- and Ψ/m5C-modified miRNA switches by endogenous
miRNA.
(A) Real-time PCR analysis of the indicated miRNA expression in HUVEC, VSMC and
HeLa normalized to U18. (B-G) Representative immunoblots of GFP and GAPDH
expression (B, D and F) and densitometric quantification (C, E, and G) of HUVEC (B
and C), VSMC (D and E) and HeLa (F and G) cells transfected with the indicated
miRNA switch. GFP and GAPDH expression were measured after 24 hours. Data
represent the mean ± SEM, normalized against GAPDH and relative to GFP transfected
control. *p < 0.05 versus GFP transfected cells. Numbers above bars indicate the mean
values.
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In HeLa cells, Ψ-modified GFP-4x21TS switches produced 50.0% relative GFP
expression, while Ψ/5mC-modfied GFP-4x21TS switches were further reduced to
39.1% relative GFP expression. No silencing was seen with Ψ- or Ψ/m5C-modified
GFP-4x126TS or GFP-4x145TS switches (Figure 5.9 F and G). These data indicate
that the silencing of Ψ- or Ψ/m5C-modified miRNA switches may be influenced by the
abundance of the cognate miRNA and/or cell type.

Silencing of modified miRNA switches is affected by the degree of complementarity of
the miRNA target sites
To determine whether the miRNA dependent silencing of modified mRNA is
affected by the degree of complementarity of target sites, we designed a GFP encoding
mRNA that included two 7mer-A1 target sites complementary to the seed region of miR126-3p in the 3'UTR (GFP-2x126seed) and compared it to GFP-2x126TS (Figure 5.10
A). Two target sites were purposely selected to ensure that we could detect any
increase or decrease in the ability of miRNA to silence the miRNA switch. In AdHEK293 cells transfected with unmodified GFP-2x126seed or GFP-2x126TS, miR-1263p mimics decreased GFP protein levels to 20.6% or 26.4%, respectively, compared to
vehicle controls (Figure 5.10 B and C). Increasing the percentage of Ψ from 0% to
100% reduced the silencing of GFP-2x126seed by miR-126-5p mimics from 20.6% to
44.9% (p < 0.05), in contrast to GFP-2x126TS, which exhibited relatively equal GFP
expression at all percentages of Ψ substitution (Figure 5.10 B and C). Cells transfected
with Ψ/m5C-modified GFP-2x126seed also exhibited impaired miRNA-dependent
silencing compared to unmodified GFP-2x126seed miRNA switches (41.6% vs. 20.6%,
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p < 0.05) and to Ψ/m5C-modifed GFP-2x126TS (41.6% vs. 18.0%, p < 0.05) (Figure
5.10 B and C).
Strikingly, when 100% Ψ- or 100% Ψ/m5C-modified GFP-2x126seed miRNA
switches were transfected into HUVEC, we observed no decrease in GFP expression
compared to 100% Ψ- or 100% Ψ/m5C-modified GFP mRNA. Whereas, 100% Ψ- and
100% Ψ/m5C-modified GFP-2x126TS reduced GFP expression to 23.9% and 66.3% (p
< 0.05), respectively (Figure 5.10 D and E). The silencing of Ψ-modified GFP-2x126TS
was significantly stronger than the silencing of Ψ-modified GFP-2x126seed (p < 0.05),
but no difference was observed between the Ψ/m5C-modified miRNA switches.
Interestingly, 100% Ψ/m5C-modified GFP-2x126TS was significantly less silenced than
100% Ψ-modified GFP-2x126TS (Figure 5.10 D and E), an effect that was not seen
when using GFP-4x126TS miRNA switches in the same cells (Figure 5.9 B and C).
These data indicate that nucleotide modifications largely inactivates miRNA switches
containing partial complementarity to the mature miRNA sequence.

m1Ψ-modification affects the silencing of miRNA switches
Recently, it has been reported that mRNAs containing m1Ψ-modification
outperformed the Ψ- and Ψ/m5C-modified mRNA platforms 103,106. Therefore, we
compared the silencing of GFP-4x126TS containing 100% m1Ψ substitutions to
unmodified, 100% Ψ- or 100% Ψ/m5C-modified miRNA switches in Ad-HEK293 cells. In
the presence of miR-126-3p mimics, m1Ψ-modified GFP-4x126TS exhibited 31.8%
relative GFP expression (p < 0.05) and was significantly different than unmodified GFP-
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4x126TS that showed only 6.8% GFP expression relative to vehicle controls (Figure
5.11 A and B).
In the presence of miR-126-3p mimics, cells transfected with unmodified GFP4x126TS were only 4% GFP positive at day one, whereas Ψ-, Ψ/m5C- or m1Ψ-modified
GFP-4x126TS transfected cells were 22%, 18.7% and 47% GFP positive, respectively.
The percent GPF positive cells decreased to < 2% at day five in all miR-126-3p mimic
treated groups (Figure 5.12 A-D). These data show that the nucleotide modifications,
particularly m1Ψ, increase the translation and extend the duration of protein expression
thereby reducing the silencing efficiency of the miRNA switches.
We also tested whether 100% m1Ψ-substitution affects silencing of the other
miRNA switches in Ad-HEK293 cells and found that m1Ψ-modified GFP-4x21TS, GFP4x145TS and GFP-4x122TS, exhibited 19.4%, 32.9%, and 21.0% GFP expression,
respectively, in the presence of their cognate miRNA mimic (p <0.05). Unmodified GFP4x21TS, GFP-4x145TS, and GFP-4x122TS showed 10.5%, 11.0%, and 9.5% relative
GFP expression, respectively. Although the m1Ψ-modified miRNA switches tended to
be less effectively silenced by the cognate miRNA than the unmodified miRNA
switches, these differences did not reach statistical significance (Figure 5.11 C and D).
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Figure 5.10. miRNA target site complementary affects the silencing of Ψ- and
Ψ/m5C-modified miRNA switches.
(A) Sequences of mature miR-126-3p, fully complementary or 7mer-A1 seed target
sites. ^ denotes the site of Argonaute cleavage. Red bases are complementary to the
seed sequence. (B-E) Representative immunoblots (B and D) and densitometric
quantification (C and E) of Ad-HEK293 cells transfected with miR-126-3p, miR-143-3p
mimics or vehicle control 24 hours before transfection with the indicated miRNA switch
(B and C) or HUVECs transfected with the indicated miRNA switches (C and D). GFP
and GAPDH expression were measured after 24 hours. Data represent the mean ±
SEM, normalized against GAPDH and relative to vehicle control (C) or GFP transfected
cells (E). *p < 0.05 versus miR-143 control (C); versus GFP treated cells (E). # p < 0.05
for the indicated comparisons. Numbers above bars indicate the mean values.
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Figure 5.11. Silencing of modified miRNA switches is affected by the location of
the miRNA target sites.
(A-F) Representative immunoblots (A, C and E) and densitometric quantification (B, D
and F) of Ad-HEK293 cells transfected with the indicated miRNA mimics or vehicle
control 24 hours before transfection with the indicated miRNA switches. GFP and
GAPDH expression were measured after 24 hours. Data represent the mean ± SEM,
normalized against GAPDH and relative to vehicle control. *p < 0.05 versus miR-143
treated control. #p < 0.05 for the indicated comparisons. “NTC” indicates nontransfected control. Numbers above bars indicate the mean values.
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Figure 5.12. Long-term kinetics of miRNA switch silencing.
(A-E) Ad-HEK293 cells were transfected with the indicated miRNA mimic or vehicle
control 24 hours prior to transfection with GFP-4x126TS miRNA switches with the
indicated nucleotide modifications and control Ψ/m5C-modified niRFP mRNA. GFP and
RFP expression was analyzed by flow cytometry of 5000 cells every 24 hours after
transfection.
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Addition of miRNA target sites at the 5'UTR of the miRNA switches counteract the
impact of nucleotide modification
A recent reports has shown that placing miRNA target sites in the 5'UTR of the
miRNA switches produced stronger miRNA dependent silencing 144. To test whether the
addition of miRNA target sites at the 5’UTR could counteract the impact of nucleotide
modifications on the silencing of miRNA switches, we designed GFP-encoding miRNA
switches with one fully complementary target site for miR-126-3p in the 5’ UTR of
human b-globin (5'UTR-1x126TS-GFP). In Ad-HEK293 cells transfected with
unmodified 5'UTR-1x126TS-GFP, miR-126-3p reduced GFP expression to 1.1% in the
presence of miR-126-3p mimics (Figure 5.11 E and F). The suppression of GFP was
equivalent to that of the four miR-126-3p target sites in the 3’ UTR (Figure 5.11 A and
B). Moreover, cells transfected with 100% Ψ-, 100% Ψ/m5C, and 100% m1Ψ-modifed
5'UTR-1x126TS-GFP switches also showed significant silencing by miR-126-3p
compared to miR-143-3p controls (9.0%, 10.9%, and 5.7%, respectively p<0.05). These
data indicate that placing one fully complementary miRNA target sites at the 5’UTR of
miRNA switches eliminates the impact of m1Ψ-modfication seen when using four target
sites at the 3'UTR.

Discussion
miRNAs have increasingly been used to build regulatory circuits in synthetic
biology. miRNA switches have been recently used to enable cell-specific expression of
IVT mRNA. Nucleotide modifications are commonly incorporated in these IVT mRNA to
decrease immunogenicity and increase translation. In this manuscript we sought to
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investigate the influence of modified nucleotides on the performance of miRNA
switches. We found that incorporation of Ψ and m1Ψ, which increase translation, tend
to decrease the miRNA-dependent regulation of miRNA switches, while Ψ/m5C
modification enables one miRNA target site at the 3’ UTR to regulate the miRNA switch
as effectively as four target sites. We also demonstrated that the effects of Ψ, Ψ/m5C,
and m1Ψ modification are sequence dependent and are not correlated with the
proportion of modified nucleotides in the miRNA target site. Furthermore, modified
miRNA switches containing seed complementary target sites are poorly regulated by
miRNA, while placing the miRNA target site in the 5’ UTR makes the miRNA-dependent
silencing largely insensitive to nucleotide modification (Table 5.1).

Table 5.1. Summary of miRNA switch silencing in Ad-HEK293 cells.
The mean GFP expression from the indicated miRNA switches relative to the
unmodified miRNA switch in the presence of their cognate miRNA mimics.

GFP-1x126TS
GFP-2x126TS
GFP-3x126TS
GFP-4x126TS
GFP-4x21TS
GFP-4x145TS
GFP-4x122TS
GFP-2x126seed
5'UTR-1x126TS-GFP

Unmodified
0.235
0.264
0.077
0.068
0.105
0.11
0.095
0.206
0.011

Ψ
0.364
0.35
0.236
0.123
0.415
0.438
0.116
0.449
0.09

Ψ/m5C
0.184
0.18
0.135
0.145
0.256
0.326
0.202
0.416
0.109

m1Ψ
N/A
N/A
N/A
0.318
0.194
0.329
0.21
N/A
0.057

N/A: Not assessed

The relative contribution of the endonuclease cleavage and/or suppression of
translation in the dynamics of miRNA-mediated mRNA silencing has not been fully
elucidated, but ultimately, both pathways contribute to the decrease in protein
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expression. To explore the differences in miRNA-dependent silencing between
unmodified and modified miRNA switches we measured changes at the protein level,
which also accounts for the increase in mRNA translation seen with the modifications.
We explored different methods for measuring protein expression (flow cytometry and
immunoblotting) and carefully quantified and pooled the data when possible. Although
immunoblotting is not the most sensitive method of measuring protein expression but it
was sufficient for our initial assessments. Further studies that use more sensitive
assays are necessary to pinpoint the exact mechanisms by which nucleotide
modification alters miRNA-dependent silencing. We also took advantage of the fact that
Ad-HEK293 cells lack expression of most TLRs 102,103,279 and tolerate transfection with
unmodified IVT mRNA. Although Ad-HEK293 cells displayed minimal toxicity when
transfected with unmodified IVT mRNA, we noticed lower expression of Ψ/m5C-modifed
niRFP mRNA when co-transfected with unmodified GFP-4x126TS (Figure 5.12 A). This
trans-repression is likely due to the presence of other pattern recognition receptors such
as Protein Kinase R (PKR), which phosphorylates the eukaryotic translation initiation
factor eIF2a and leads to translation inhibition 280. Previous studies have performed
similar experiments in Ad-HEK293 cells to show that incorporation of modified
nucleotides in IVT mRNA reduces PKR activation, 2'-5'-oligoadenylate synthetase and
RNase L activity 102,105,108.
Here we found that 100% Ψ substitution doubled the expression of IVT-mRNA
compared to unmodified mRNA and slightly reduced miRNA-mediated silencing of all
the tested miRNA switches but did not reach statistical significance. Similar results were
also observed with m1Ψ-modification, which is known to produce even more protein
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expression than Ψ-modification, and it significantly reduced the miRNA-dependent
silencing of miR-126-3p switches. These data are in line with previous reports showing
that incorporation of Ψ or m1Ψ in IVT mRNA enhanced translational efficiency 103,106,281.
Moreover, alterations in mRNA translation initiation, for example tethering of the
translation factors eIF-4E or eiF-4G to an mRNA, have been shown to confer resistance
to miRNA-induced repression 282. We also found that the increased silencing of Ψmodified miRNA switches with multiple fully complementary target sites at the 3’ UTR
was due to an increase in translational repression rather than transcript degradation.
Moreover, miRNA switches drastically reduced the availability of the endogenous
miRNA. The miRNA sponging was similar when using miRNA switches with one or four
fully complementary target sites. Previous studies using plasmids or viral vectors have
reported no sponging activity even when using four fully complementary target sites 276.
The differences in miRNA sponging might be due to the temporal expression between
the two delivery systems. Plasmids and viral vectors are gradually transcribed and
transported to the cytoplasm are less likely to sponge the miRNA, whereas transfection
of miRNA switches can immediately bind and potentially saturate the available miRNA
due to rapid delivery of a high number of transcripts into the cytoplasm. However,
because miRNA switches are transient, the sponging caused by the miRNA switches is
temporary.
Similar to Ψ-modified mRNA, Ψ/m5C-modified mRNAs are also known to
enhance protein expression and reduce immunogenicity 103. However, in contrast to Ψmodified miRNA switches, the addition of one miRNA target site to the 3'UTR produced
miRNA-dependent silencing of Ψ/m5C-modified miR-126-3p switches as effectively as
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when four target sites were used. Moreover, this effect was detected not only in AdHEK293 cells, but also occurred in HUVECs. The proportion of m5C in the target sites
of the tested miRNA switches did not correlate with the miRNA-dependent silencing
efficiency, and the silencing efficiency also varied in different cell types used in this
work. Nucleotide modification alters the secondary or tertiary structure of the mRNA 111
which may alter accessibility of the miRNA target sites in a switch-specific manner. In
fact, Ψ-modification has been reported to reduce protein binding to consensus
sequences in mRNA 283. The nucleotide modifications may also affect the kinetics of
miRNA switch shuttling in or out of p-bodies 284,285. Further studies are necessary to
explore the interaction of miRNA target site sequence and the changes in miRNAdependent silencing caused by nucleotide modifications, especially because previous
reports have shown enrichment of m5C at site of Argonaute binding 286 and differences
in protein expression from modified mRNA in different cell types 274.
The design of miRNA target sites and its location in a miRNA switch can have a
large impact on the capacity for miRNA-mediated silencing. Our results showed that
nucleotide modifications have a larger effect on the silencing of miRNA switches that
utilize target sites complementary to the seed sequence of the mature miRNA.
Because the majority of miRNA target sites in animals utilize seed complementary
target sites 287,288, post-transcriptional modification of mRNAs may provide an additional
level of control over gene expression by tuning miRNA activity. An important feature of
the miRNA:mRNA interaction is the thermal stable base-pairing between the miRNA 5′
end (residues 2-7) and the mRNA target. In addition, efficient endonuclease cleavage
by Argonaute 2 requires base pairing at the site of cleavage, between bases 10 and 11
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289–291

. Previous reports have shown that miRNA-mediated silencing primarily occurs

though direct cleavage of the targeted mRNA by Argonaute 2 when bound to a fully
complementary target site 282,292,293. However, the silencing of partial complementary
target genes occurs by translational repression and/or mRNA decay in a manner
independent of endonucleolytic cleavage. Binding of the RISC has been show to recruit
several proteins including GW182, which can mediate poly(A)-binding protein
displacement, recruit translational repressors and/or dissociate eIF4A from the capbinding complex eIF4F 282,294.
Additionally, we show that placing one fully complementary miRNA target site at
the 5’ UTR eliminates the influence of the nucleotide modifications seen with the four
target sites at the 3'UTR of the miRNA switches. The increase in silencing efficiency
when using miRNA target sites at the 5’ UTR was most pronounced in the m1Ψmodified miR-126-3p switches. These data are in agreement with previous work that
showed that modified miRNA switches with four miRNA target sites at the 3'UTR are
less effective than one target site at the 5'UTR 144. Silencing of miRNA switches by
miRNA target sites in the 3’UTR and the 5’UTR has been shown to involve
deadenylation and cap-dependent translation inhibition 295. However, the enhanced
silencing of the modified miRNA switches with one fully complementary miRNA target
site at the 5'UTR indicates that there may be another mechanism triggered by miRNA
target sites in the 5’UTR. One potential explanation is that direct Argonaute 2-mediated
cleavage of the targeted miRNA switch upstream of the start codon may be more
effective in silencing due to the removal of initiation factors that are bound to the 5’ cap;
whereas cleavage at the 3’ UTR promotes transcript degradation by removing the
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stabilizing poly(a)-tail. It is also possible that RISC binding at the 5’ UTR interferes with
translation machinery through steric hindrance of ribosome assembly 296. Furthermore,
a miRNA target site near the start codon may be more accessible to the RISC as it has
less secondary structure than other regions of mRNA 297. Further studies are needed to
fully explain the enhanced activity of miRNA target sites at the 5’ UTR.
Based on the data presented here, several important considerations must be
taken into account when designing effective modified miRNA switches. First, it is crucial
to ensure that the selected miRNA is expressed in a cell-specific manner. Second, the
endogenous expression levels of the selected miRNA must be abundant. Third, use a
fully complementary miRNA target sites and not miRNA seed sequences. Fourth,
including multiple miRNA target sites increases the miRNA-mediated suppression of the
miRNA switch. Fifth, placing the miRNA target sites at the 5’UTR will result in effective
miRNA-dependent silencing and eliminate the reduction in silencing caused by
nucleotide modification. However, switches with miRNA target sites at the 5’UTR
increase translation in some instances 298 and therefore should be tested to ensure
switch activity. Lastly, the dose of miRNA switches should be fine-tuned to prevent
saturation of endogenous miRNA.
The present study is of broad significance given the dynamic changes in the
naturally occurring modified nucleotides in all cellular mammalian RNA. The impact of
these modifications on miRNA-mediated silencing provides a new mechanism of gene
regulation at the epitranscriptome level, which has not been explored. This work
provides insights into the influence of the naturally occurring nucleotide modifications on
miRNA-dependent silencing and informs the design of optimal miRNA switches.
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Furthermore, given that modified nucleotides increase translation, they can serve as a
novel tool to elucidate the relative contribution of the endonuclease cleavage and/or
suppression of translation in the dynamics of miRNA-mediated mRNA silencing.
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Chapter 6
Systemic administration of self-assembled p5RHH-based nanoparticle delivers
synthetic mRNA to plaques in a mouse model of atherosclerosis
Note to the Reader
This work was produced in collaboration with Jeffrey VanWye, Dr. John Canfield,
Dr. Ezinne Francess Mong, Dr. Samuel Wickeline, Dr. Hua Pan, and Dr. Hana TotaryJain. H.T.J. conceived the idea. J.L., J.V. and H.T.J. designed the research, performed
the experiments, and analyzed the data. J.C. and E.M. performed the experiments. J.L.
and H.T.J. wrote the paper. S.W. and H.P. provided conceptual and practical advice on
experimental plans, contributed reagents and mice, and reviewed all data. All authors
reviewed and edited the manuscript.

Introduction
RNA therapeutics are a promising new class of biological drugs that are under
active development for a variety of human diseases. mRNA therapeutics in particular
have a variety of potential applications, including protein replacement therapy ,
CRISPR/Cas9 gene editing 167, and vaccines against various viruses 171,172,299–301. The
use of mRNA therapeutics offers advantages over traditional DNA or viral gene therapy
vectors as there is no risk of insertional mutagenesis, and the rapid expression of the
encoded proteins does not require cellular division. In addition, mRNA therapeutics can
encode any gene regardless of the length of the coding sequence to yield proteins with
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appropriate post-translational modifications. For example, the cell-free production and
the tight quality control possible with mRNA therapeutics has proven beneficial in the
rapid generation of mRNA-based vaccines in response to disease outbreaks 171,302.
Despite recent advances in RNA structural chemistry 86,303, the safe and efficient
delivery of the RNA molecules remains a major hurdle. RNA molecules are highly
charged and too large to cross cellular membranes on their own. While synthetic RNA
molecules may be taken up by cells via endocytosis, they produce little biological
activity due to endosomal entrapment and degradation in lysosomes. Modifications to
the phosphodiester backbone may enhance endosomal escape but only for small
single-stranded RNA such as siRNA 304. Larger RNA molecules such as mRNA can be
delivered to cytoplasmic compartments by physical transfection methods such as
microinjection or electroporation, but these approaches are unsuitable for systemic
delivery in vivo.
Cationic lipids and polymers can package RNA into nanoparticles that are taken
up by cells to effect a measure of endosomal escape. However, the strong positive
charge carried by these nanoparticles promotes opsonization by serum proteins and
uptake by the mononuclear phagocyte system, particularly by Kupffer cells in the liver
305

. In recent years, extensive work has been dedicated to the refinement of these

nanoparticles by using ionizable lipids and polymers that are only cationic in acidic
environments such as maturing endosomes 306. While pH sensitive nanoparticles exhibit
reduced liver toxicity compared to cationic nanoparticles, they still become trapped in
the liver. Modulating the composition of the nanoparticles by including different lipids or
adding targeting components to the nanoparticle shell can provide a degree of organ
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specificity 229,256. However, synthesis of such nanoparticle systems can be complex,
requiring precise microfluidic assembly followed by separation and purification steps.
We recently designed and tested a modified and systemically safe version of the
natural cell penetrating peptide melittin by amino-terminus truncation and inclusion of
positively charged residues at the C-terminus, named “p5RHH”, that rapidly interacts
with short negatively charged oligonucleotides such as siRNA to form 55 nm particles
spontaneously upon mixing. These nanoparticles are taken up by macropinocytosis and
traffick through endosomes. As the interior pH of endosomes drops due to vacuolar
ATPase (vATPase) activity during maturation, the histidine residues become protonated
and the p5RHH nanoparticles disassemble 241, perhaps due to the repulsive force of the
greater cationic charge overcoming the hydrophobic force that gives the nanoparticle its
structure. The free p5RHH, which is membrane-lytic only in high concentrations in the
endosome, induces endosomal lysis and release of the siRNA. Importantly, the
concentration of the free p5RHH released in the cytoplasm is insufficient to disturb the
plasma membrane, which maintains cell viability 241.
The p5RHH-siRNA nanoparticles are effective in targeting NFKB subunit p65 in
mouse models of arthritis 242–244, JNK2 in the plaques of atherosclerotic mice 246 and
AXL in a xenograft mouse model of ovarian cancer 245. However, the ability of p5RHH to
bind mRNA, form nanoparticles and effectively deliver it to the cellular cytoplasm to be
translated has not been tested. The present study demonstrates that p5RHH
spontaneously forms nanoparticles in the presence of synthetic mRNA. These
nanoparticles were able to protect the mRNA from degradation and efficiently deliver it
to cells to be translated. Moreover, systemic administration of p5RHH-near infrared
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florescent protein (niRFP) encoding mRNA nanoparticles in ApoE knockout mice
resulted in high expression of niRFP only in the atherosclerotic plaque regions, whereas
niRFP was not detected in regions of intact endothelium or other organs.

Results
p5RHH spontaneously forms nanoparticles with synthetic mRNA
The p5RHH comprises 21 amino acids with a hydrophobic core and a cationic Cterminus tail that contains 5 arginine and 2 histidine residues (Figure 6.1 A). The Cterminus of p5RHH carries a strong positive charge that enables the peptide to interact
electrostatically with the negatively charged backbone of nucleic acids. To examine the
interaction of p5RHH with mRNA, a gel retardation assay was performed using 350 ng
in vitro transcribed Cy5-uridine labeled GFP-coding mRNA (to allow for visualization)
incubated with increasing amounts (0 - 2.5 nmol) of p5RHH. Given the positive charge
of p5RHH, we anticipated that only free unbound mRNA would migrate when an electric
field was applied. As expected, a single band of ~1100 nt migrated in the agarose gel
when free Cy5-uridine labeled GFP mRNA was loaded. Incubation of Cy5-labled GFP
mRNA with increasing amounts of p5RHH decreased the free mRNA signal and shifted
the Cy5 signal to the loading well, indicating that the Cy5-labled GFP mRNA was bound
to the p5RHH peptide and formed a complex that did not migrate through the agarose
gel when the electrical field was applied (Figure 6.1 B).
To determine the optimal conditions for the formation of nanoparticles, 350 ng
GFP mRNA was mixed with 2 nmol p5RHH and incubated at 4, 20 or 37°C for 40
minutes, or incubated at 37°C for 5, 10, 20, 40, 60 or 120 minutes before adding it to
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B16F10 cells. After 24 hours, the percentage of GFP positive cells was determined by
flow cytometry. Incubation temperature of 37°C and incubation times of 20 or 40 min
displayed the highest transfection efficiencies (Figure 6.1 C,D). Therefore, all
nanoparticles in the subsequent experiments were tested under these conditions.
We also tested the duration of GFP expression over time in B16F10 cells
transfected with GFP-p5RHH and detected GFP positive cells by flow cytometry up to
nine days after transfection (Figure 6.1 E).

mRNA and p5RHH form consistent nanoparticle size regardless of mRNA length
To determine the optimal mRNA-p5RHH ratios that results in the highest
transfection efficiency and the lowest cytotoxicity, 714 nt in vitro transcribed GFP mRNA
(350 ng) was incubated with increasing amounts (0 - 2.5 nmol) of p5RHH, and B16F10
cells were transfected with the resulting nanoparticles. After 24 hours, GFP- and
propidium iodide- (PI) positive cells were determined by flow cytometry. Cells
transfected with GFP mRNA complexed with increasing amount of p5RHH resulted in
an increased percentage of GFP positive cells that reached a maximum of 75% at 2
nmol p5RHH (Figure 6.2 A).
We also tested whether the optimal mRNA-p5RHH ratios is affected by mRNA
length. Therefore, 350 ng of mRNA encoding near infrared fluorescent protein 670
(niRFP, 936 nt), firefly luciferase (Luc, 1653 nt), or self-replicating mRNA derived from
the Venezuelan equine encephalitis virus expressing GFP (VEE-GFP, 8600 nt) were
incubated with increasing amounts (0 - 2.5 nmol) of p5RHH. After 24 hr, transfection
efficiency of niRFP mRNA-p5RHH and VEE-GFP mRNA-p5RHH, as well as luciferase
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activity from Luc mRNA-p5RHH all peaked at the same ratio of 350 ng mRNA to 2.0
nmol p5RHH, similar to the 714 nt GFP mRNA-p5RHH (Figure 6.2 A-D). However, the
transfection efficiency of VEE-GFP mRNA-p5RHH was lower than the other
nanoparticles (Figure 6.2 D). Therefore, in all subsequent experiments we used a ratio
of 350 ng synthetic mRNA to 2 nmol p5RHH.
To visualize and measure the diameter of each of the different mRNA-p5RHH
nanoparticles, scanning electron microscopy imaging was performed at the optimized
ratio of mRNA to p5RHH (350 ng mRNA : 2.0 nmol p5RHH). Strikingly, compact
spherical nanoparticles with an average diameter of < 200 nm were observed for each
of the tested mRNA (Figure 6.2 E-H). Interestingly, the niRFP, Luc, and VEE-GFP
mRNA nanoparticles were very similar sizes, while the GFP mRNA nanoparticles were
significantly smaller (Figure 6.2 E-H). Despite the difference in sizes, the zeta potential
measurement of the different mRNA-p5RHH nanoparticles showed an effective surface
charge of approximately +6 mV for each nanoparticle. These results demonstrate that
the physical characteristics of mRNA-p5RHH nanoparticles are consistent even when
formed with different mRNA payloads, which may increase the reproducibility of
nanoparticle transfections in vitro and in vivo.
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Figure 6.1. p5RHH spontaneously forms nanoparticles when mixed with synthetic
mRNA.
(a) Predicted structure, hydrophobicity and charge density plots for p5RHH. (b) mRNA
loading assay of 350ng of 5% Cy5-uridine labeled GFP mRNA (~1000nt) complexed
with the indicated amounts of p5RHH. Cy5 signal is shown in red, ethidium bromide
staining is shown in white. (c-d) Flow cytometry of B16F10 cells 24 hours after
transfection with GFP mRNA-p5RHH nanoparticles complexed for 40 minutes at the
indicated temperature (c) or the indicated time at 37 ˚C (d). (e) Flow cytometry of
B16F10 cells at the indicated number of days after transfection with p5RHH-GFP
nanoparticles. Cells were re-plated at a 1:5 dilution on day 5. Data represent the mean
± SEM of three independent experiments.
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Figure 6.2. p5RHH-mRNA nanoparticles with payloads of various lengths.
(a-d) Flow cytometry (a, b and d) and luciferase assay (c) of B16F10 cells 24 hours
after treatment with the indicated amount of p5RHH complexed with 350 ng of GFP (a),
niRFP (b), Luc (c) or VEE-GFP (d) mRNA. (e-h) Representative scanning electron
microscopy images accompanied by dot plot of sizes of p5RHH nanoparticles loaded
with GFP (e), niRFP (f), Luc (g) or VEE mRNA (h) on a polycarbonate membrane with
200 nm pores (dark circles). Data represent the mean ± SEM of three independent
experiments (a-e).
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Effective mRNA release of the mRNA-p5RHH nanoparticles require endosomal
acidification
To confirm that mRNA-p5RHH nanoparticles traffic through endosomes, B16F10
cells were transfected with 5% Cy5- labeled GFP mRNA-p5RHH nanoparticles. Cells
were treated with 1 µM bafilomycin, an inhibitor of endosomal acidification, or vehicle
control. Particle uptake, measured by percent Cy5-positive cells, and percent GFPpositive cells were determined by flow cytometry at 40 minutes and 24 hours after
transfection. While no GFP-positive cells were detected after 40 min of transfection,
~65% of the cells were Cy5-positive in both bafilomycin treated or untreated cells,
indicating that bafilomycin does not affect cellular uptake of the nanoparticles (Figure
6.3 A,B). After 24 hours, 56.7% of the untreated cells were GFP-positive, whereas
bafilomycin treated cells exhibited only 14.6% (p< 0.05), even though the percent of
Cy5-positive cells was still at ~65% in both groups (Figure 6.3 A,B). These data
indicate that mRNA-p5RHH nanoparticles are rapidly taken up by cells, traffic through
the endosomes and require endosomal acidification to efficiently transfect cells.

mRNA-p5RHH nanoparticles possess inherent endosomal escape
Next, we tested whether addition of chloroquine, a known endosomolytic agent,
enhanced the transfection efficiency by inducing endosomal release of the mRNAp5RHH nanoparticles that may be still trapped in the endosomes. Again, B16F10 cells
were transfected with 5% Cy5-uridine labeled GFP mRNA-p5RHH nanoparticle and
treated with vehicle or with 50 µM chloroquine. The percentages of Cy5- and GFPpositive cells were determined by flow cytometry 40 minutes and 24 hours after
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transfection. After 40 min of transfection, cells treated with chloroquine showed no
significant difference in the percent of Cy5-positive cells compared to vehicle treated
cells (67.2% vs. 65.1%) and no GFP-positive cells were detected, indicating that
chloroquine does not affect cellular uptake of the nanoparticles (Figure 6.3 C,D).
Importantly, after 24 hours, despite the small increase (76.9% vs. 69.3%) in Cy5positive cells, no change in the percent of GFP-positive cells (56.8% vs. 55.7%) was
found between chloroquine treated or untreated cells (Figure 6.3 C,D) indicating the
efficient transfection efficiency of GFP mRNA-p5RHH nanoparticles is due to the
intrinsic membrane-lytic activity of p5RHH 241.

mRNA-p5RHH nanoparticles does not induce cytotoxicity
To ensure that the endosomolytic activity of the mRNA-p5RHH nanoparticles
does not induce apoptosis of the transfected cells, we measured the percent of
propidium iodide (PI)- positive B16F10 cells after transfection with GFP-mRNA p5RHH
nanoparticles at various mRNA to peptide ratios. After 24hr we observed no significant
increase in PI-positive cells at any of the tested ratios (Figure 6.4 A,B), indicating that
the unbound p5RHH released after endosomolysis does not induce significant cell
death.
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Figure 6.3. Endosomal escape of p5RHH-mRNA nanoparticles.
(a-d) Flow cytometry of B16F10 cells at the indicated timepoint after treatment with 5%
Cy5-uridine labeled GFP mRNA-p5RHH nanoparticles in the presence 1 µM bafilomycin
(a and b) or 50 µM chloroquine (c and d). Data represent the mean ± SEM of three
independent experiments. * p < 0.05 nanoparticle + vehicle treated cells (b and d).
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Figure 6.4. mRNA-p5RHH nanoparticles exhibit minimal cytoxicity and RNase
sensitivity.
(a and b) Flow cytometry with propidium iodide of B16F10 cells 24 hours after treatment
with mRNA-p5RHH nanoparticles formed by complexing 350 ng of GFP mRNA with the
indicated amount of p5RHH. (c) Gel electrophoresis of unbound and p5RHH-complexed
Cy5-labeled GFP mRNA with or without RNaseA treatment after nanoparticle formation.
(d) Flow cytometry of B16F10 cells 24 hours after treatment with GFP mRNA-p5RHH
nanoparticles with or without RNaseA treatment after nanoparticle formation.
Pretreatment of the GFP mRNA prior to nanoparticle formation was used as a control
for RNaseA activity. Data represent the mean ± SEM of three independent experiments.
* p < 0.05 versus untransfected control (b) or no RNase treatment (d).
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mRNA-p5RHH nanoparticles protect the mRNA from degradation by RNase
Successful in vivo delivery of mRNA therapeutics requires stable nanoparticles
that can protect the synthetic mRNA from degradation. To test whether mRNA-p5RHH
nanoparticles protect their payload from degradation by RNaseA, we treated Cy5labeled GFP mRNA-p5RHH or free Cy5-labeled GFP mRNA with vehicle control or with
RNaseA for 20 min in 37˚C before analyzing the resulting products by gel
electrophoresis. Free mRNA exhibited extensive degradation by RNaseA, whereas the
mRNA complexed with p5RHH showed no mRNA degradation (Figure 6.4 C).
Treatment of GFP mRNA-p5RHH nanoparticles prior to adding them to the B16F10
cells showed no difference in percent GFP positive cells between the RNase treated or
untreated nanoparticles after 24hr (Figure 6.4 D). However, pretreatment of the GFP
mRNA with RNaseA before formation of the nanoparticles abolished GFP expression
(Figure 6.3 D). These results indicate that mRNA-p5RHH nanoparticles may withstand
serum endonucleases, which is critical for in vivo delivery of mRNA therapeutics.

mRNA-p5RHH nanoparticles exclusively target atherosclerotic plaques in ApoE-/- mice
To test the efficacy of mRNA-p5RHH nanoparticles in vivo, C57BL6/J mice were
injected intravenously with GFP mRNA-p5RHH nanoparticles and GFP expression was
assessed after 48 hours by immunoblotting lysates from the brain, heart, lungs, muscle,
pancreas, liver, spleen, kidneys and bladder. No GFP expression was detected in any
of these organs (Figure 6.5). Consistent with these results, previous studies have
showed that siRNA-p5RHH nanoparticles localize only to regions of disrupted
endothelial cell barriers in advanced atherosclerotic plaques after systemic
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administration 246. Therefore, we tested whether mRNA-p5RHH nanoparticles could
deliver a reporter mRNA in an ApoE-/- mouse model of atherosclerosis. To avoid the
autofluorescence that might mask GFP signal, mice received intravenous injection of
vehicle control or niRFP mRNA-p5RHH nanoparticles. After 48 hours, niRFP expression
in the different regions of the aorta were examined by en face confocal imaging. To
assess endothelial cell integrity, aortas were immunostained for the endothelial cell
specific marker VE-Cadherin. Strong niRFP expression was found in advanced
atherosclerotic plaques located at the aortic arch regions of the treated mice, whereas
thoracic regions that did not develop plaques exhibited no niRFP expression (Figure
6.6). Importantly, the kidneys, liver, lungs and spleen collected from the niRFP mRNAp5RHH nanoparticle treated ApoE-/- mice showed no niRFP signal by confocal
microscopy (Figure 6.7). In addition, we no niRFP mRNA could be detected in any of
these organs by RT-PCR. These results highlight the potential for treating
atherosclerosis with mRNA therapeutics utilizing the specificity and efficiency of mRNAp5RHH nanoparticles.
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Figure 6.5. Tissue distribution of p5RHH-GFP nanoparticles in C57BL6/J mice.
Representative immunoblots of GAPDH and GFP in protein lysates of the indicated
organs collected from three C57BL6/J mice 48 hours after intravenous injection of 200
µL of GFP mRNA-p5RHH nanoparticles. B16F10 cells transfected with the same
complexing reaction for each animal were used as a GFP+ control. An untreated mouse
was used as control for antibody specificity.
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Figure 6.6. Expression of p5RHH-mRNA nanoparticle payloads in the aorta of
ApoE-/- mice.
Representative confocal images of aortic arch plaques and regions of the thoracic aorta
captured from en face preparations of ApoE-/- aortas 48 hours after vehicle or niRFP
mRNA-p5RHH nanoparticle injection. Images were captured at 20x magnification,
insets magnified to 80x. Scale bars represents 100 µm. White arrowheads indicate
niRFP expressing cells.
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Figure 6.7. Tissue distribution of p5RHH-niRFP nanoparticles in ApoE-/- mice.
Representative fluorescent confocal microscopy images of the indicated organs
collected from ApoE-/- mice 48 hours after intravenous injection of 200 µL of vehicle or
niRFP mRNA-p5RHH nanoparticles. Images were taken at 20x. Scale bar represents
100 µm.
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Discussion
Synthetic mRNA therapeutics hold great promise for the treatment of myriad
diseases. Despite substantial advances in the production of the synthetic mRNA, the
limitations of existing delivery platforms severely hinder its clinical development.
Identification of novel delivery vehicles that prevent degradation and effectively deliver
the mRNA are crucial for the expansion of this promising class of therapies. The present
study demonstrates that p5RHH peptides in the presence of mRNA spontaneously form
compact nanoparticles across a range of mRNA sizes. These nanoparticles are highly
RNase resistant, readily taken up by the cells, and efficiently and safely release the
mRNA from the endosomes to be translated. Moreover, systemic delivery of p5RHHniRFP nanoparticle in atherosclerotic mice generated high expression levels of the
synthetic mRNA exclusively in atherosclerotic plaque regions.
The natural cell-penetrating peptide melittin is the major pore-forming component
of bee venom. In prior work, we substantially modified its cell lytic activity by aminoterminus truncations to produce a new peptide, “p5”, which still allowed it to stably but
safely insert into cell membranes 239.This p5 was developed as a linker agent for
delivery of various therapeutic or diagnostic compounds into cells by the penetrating
action of the peptide 239. However, neither p5 nor melittin itself were able to condense
siRNA into a nanoparticle that was transfective (unpublished data). Upon further highly
specific modification of the C-terminus with histidines and arginines to create p5RHH, a
transfective particle was enabled for siRNA delivery 240,241.
Alternative formulations of the native membrane lytic melittin have been reported
to promote endosomal escape and efficient release of the DNA into the cytoplasm after
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covalent attachment to polyethylenimine 234. In this case, to limit the inherent toxicity of
native melittin to endosomes, additional pH-sensitive protecting groups were conjugated
to mask melittin’s pore forming activity at neutral pH, which then could be removed upon
endosomal acidification 237. However, this strategy ultimately proved to exert
unacceptable levels of toxicity, prompting the termination of clinical trials against
Hepatitis B (NCT02452528).
In contrast, the p5RHH is an N-terminal truncation of melittin that retains a 13 aa
hydrophobic core combined with a modified cationic C-terminus composed of five
arginine and two histidine residues. The p5RHH peptide initiates formation of
nanoparticles through electrostatic interactions with negatively charged siRNA
molecules, which remain stable in circulation as a complex at neutral pH. As the peptide
is not free, its cytotoxicity is minimized until the entire particle is disassembled in the
endosome at lower pH 240. In analogous fashion, the p5RHH rapidly interacts with
mRNA molecules of different sizes to self-assemble nanoparticles with high transfection
efficiency and minimal cytotoxicity. Despite the 50-fold difference in GFP mRNA to
siRNA length or even 400-fold difference in the case of the VEE-GFP mRNA, the
optimal charge ratio of p5RHH and synthetic mRNA (+10:-1) was similar to that
previously reported for p5RHH and siRNA (+12:-1) 240, because the mass-to-charge
ratio of nucleic acids is essentially constant. Therefore, the ratio of 350 ng synthetic
mRNA to 2 nmol p5RHH, which produces the optimal charge ratio, might be scaled up
or down to deliver a range of lengths of RNA, from siRNA to 8kb long mRNA, and
perhaps beyond.
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Measurement of the p5RHH-mRNA nanoparticles size and surface charge
revealed compact spherical structures that were <200 nm in diameter with a +6 mV zeta
potential for all of the tested mRNA. Because the cell membrane is a negatively charged
surface, the nanoparticles’ positive surface charge may increase cellular uptake by
endocytosis 307. In addition, the small magnitude of the surface charge may minimize
opsonization by serum proteins and clearance by the mononuclear phagocyte system,
thereby avoiding sequestration in the liver and spleen. Prior work with p5RHH-siRNA
nanoparticles has shown that uptake is mediated by macropinocytosis and trafficks
through endosomes 241. Given the similar formation kinetics and in vivo behaviors of the
p5RHH-mRNA nanoparticles, we propose that the same mechanisms for cellular
interactions would be responsible for p5RHH-mRNA nanoparticles.
Trafficking of synthetic mRNAs from endosomes into the cytoplasm represents a
major rate-limiting step for many delivery approaches, with typical endosomal escape
efficiencies of around 1-2% 218. The present study demonstrates that the endosomal
escape of p5RHH-mRNA nanoparticles is highly efficient since inducing complete
endosome lysis with chloroquine did not potentiate transfection. We also show that the
intrinsic endosomolytic activity of p5RHH-mRNA nanoparticles requires endosomal
acidification to release the payload mRNA into the cytosol, where it can be rapidly
translated into protein. Indeed, we observed that the entire process from addition of the
p5RHH-mRNA nanoparticles to visible GFP expression takes less than one hour in
vitro.
Previous work by Hou et al has shown that protonation of the two histidine
residues (pKa ~6) of p5RHH is necessary for the dissociation of the p5RHH peptide
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from the nucleotide payload 240,241. The pH-dependent dissociation of p5RHH-siRNA
nanoparticle was confirmed in vitro by using a dye-binding assay which showed
increasing accessibility to the free siRNA at pH ≤ 5.5 that promoted particle disassembly
241

. Once the p5RHH is dissociated from the siRNA upon endosomal acidification, the

free p5RHH causes endosomal disruption, which was confirmed by release of the
endosomal dye acridine orange into the cytoplasm of p5RHH-siRNA nanoparticle
treated cells. Importantly, a p5RHH analog peptide p5RWR, that lacks the ionizable
histidine residues was able to form nanoparticles with siRNA but failed to dissociate
from its siRNA payload and did not alter endosomal integrity. Therefore, the pHsensitive histidine residues are both necessary and sufficient for disassembling p5RHHmRNA nanoparticles, while enabling release of the peptide to permeabilize endosomes
after acidification.
Regarding mechanism, the buffering capacity of p5RHH conferred by the
ionizable histidine residues is far lower than necessary to lyse the endosomes through
osmotic pressure or “proton sponging”. Instead, p5RHH directly interacts with the
endosomal membrane leading to endosomolysis via membrane destabilization 234.
Because p5RHH was engineered deliberately to be far less potent as a membrane
disruptor in comparison to native melittin as shown earlier by Pan et al it only effects
membrane permeability in the high concentrations found in the endosome after particle
disassembly 239,308,309.
The present study also demonstrated that p5RHH-mRNA nanoparticles exhibit
minimal cytotoxicity. The binding of p5RHH to the mRNA reduces the concentration of
the free p5RHH prior to dissociation in the endosome. After endosomolysis, the
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concentration of the free p5RHH is diluted in the cytosol, preventing disruption of the
cell membrane. Previous work with pH-responsive native melittin adjuvants by
Arrowhead Pharmaceuticals has demonstrated an unacceptable level of hepatotoxicity
after systemic administration, leading to halting of a Phase 2 clinical trial for Hepatitis B
(NCT02452528), although trials have resumed using this system for subcutaneously
delivery (NCT03747224, NCT03365947). However, p5RHH has not been reported to
produce any such toxicity due to the designed attenuation of its membrane lytic capacity
and the avoidance of liver sequestration of the p5RHH-siRNA and p5RHH-mRNA
nanoparticles.
Another key requirement for an effective in vivo mRNA delivery platform is the
ability to prevent degradation of the synthetic mRNA by extracellular endonucleases.
The present study demonstrated that p5RHH-mRNA nanoparticles provided protection
from RNaseA degradation. Moreover, the transfection efficiency of p5RHH-mRNA
nanoparticles was also unaffected by RNaseA treatment, which is a promising stability
attribute for in vivo applications.
Recent advances in the design of non-viral delivery systems for synthetic mRNA
have been reported for selective targeting to specific organs 256. However, the majority
of these reports highlight selectivity that is restricted to liver, lung, or spleen. Previous
work with p5RHH-siRNA nanoparticles has demonstrated passive permeation and
prolonged residence only in regions of disrupted endothelial cell barriers but minimal
uptake in liver, lung, or spleen 241,246. The restriction of the p5RHH-mRNA nanoparticles
to leaky or damaged vasculature confers an additional level of safety for systemic
administration as tissues with intact barrier function will not accumulate particles. To
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that point, we did not observe niRFP expression in plaque free regions of the same
aortas. To our knowledge this work is the first report of nanoparticle-mediated mRNA
delivery to atherosclerotic plaques after systemic administration. Strikingly, we were
unable to detect any niRFP transcripts in other organs of the ApoE-/- mice, nor did we
detect any GFP in the organs of C57BL6/J mice after treatment with p5RHH-GFP
mRNA nanoparticles. The possibility of delivering both siRNA and mRNA
simultaneously to the same area with the same platform may provide robust control of
protein expression, which might increase both safety and specificity for future
therapeutic applications.
Other penetrating peptide-based nucleic acid delivery system have used
chemically modified transportan-derived peptides such as PepFect. However, unlike
p5RHH, the original PepFect complexes exhibit poor endosomal escape and required
chloroquine treatment 310 or conjugation of chloroquine analogs to the peptide to
increase transfection efficiency 311. In addition, no reports have demonstrated the ability
of PepFect to deliver mRNA payloads, despite success in plasmid DNA delivery.
Furthermore, the in vivo administration of the PepFect complexes lead to accumulation
in the liver or lungs, depending on the specific peptide modification 312, in contrast to
p5RHH complexes that avoid the macrophage phagocytic system as shown in this and
prior work 242,246.

Conclusions
In conclusion, we have reported a highly efficient mRNA delivery platform based
on a modified cell penetrating peptide, p5RHH. p5RHH-mRNA nanoparticles
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spontaneously assemble in solution without the need for filtering or removal of toxic
solvents. Complexing of p5RHH with mRNA payloads attenuates its membrane lytic
activity until the nanoparticles are disassembled in the acidic environment of
endosomes. These nanoparticles exhibit a unique distribution after systemic
administration, resulting in robust expression of the payload mRNA in atherosclerotic
plaques. In addition, the flexibility of complexing any RNA with p5RHH in a simple
mixing procedure may prove advantageous for both clinical and pre-clinical use.
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Chapter 7
Limitations and Overall Conclusions
Study Limitations
In our examination of the effects of modified nucleotides on the regulation of
miRNA switches, we utilized a variety of modified nucleotides at multiple percentages of
substitution. However, this does not permit the modification of specific bases and
therefore produces heterogeneity in the product transcripts. Given the enrichment of
nucleotide modifications in specific regions of endogenous mRNA, the effects of
transcript-wide incorporation of modified nucleotides may mask the effects produced by
modification of specific loci. Further studies using a nucleotide modifying enzyme fused
to an RNA-targeting Cas13 CRISPR effector, similar to reported RNA editing systems
313

, may be better able to elucidate the importance of modification location. In an

attempt to test the generality of the effects observed using the miR-126-3p switches, we
utilized switches with target sites for different miRNA. We only tested a few additional
miRNA that were specifically selected miRNA as they were known to be expressed at a
high level in various cell types. A more thorough study would have also investigated the
silencing of a cognate nucleotide-modified miRNA switches by other less robustly
expressed miRNA. Such data could also be used to determine the interaction between
the miRNA expression level and the effect of nucleotide modification on the silencing of
miRNA switches. Furthermore, testing different miRNA target sites at the 5’ UTR would
also be beneficial, though our results are supported by other published studies 144. We
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also used only one 5’ and 3’ UTR to minimize the variability of our results. Further
studies that examine these affects in different UTRs are required to further confirm the
generality of our results. In addition, a more sensitive assay, such as luciferase activity,
may better show the differences between the various miRNA switches. However, we
reasoned that the ability to normalize the expression of the GFP reporter to an
endogenous control protein, GAPDH, by immunoblotting was worth the loss in
sensitivity. Finally, the expression of GFP was assayed at the 24-hour timepoint in all of
the reported experiments, but translation of synthetic mRNA is often reported to peak
around 6-10 hours after transfection 104. Examining differences at earlier or later
timepoints may reveal other changes in regulation caused by the nucleotide
modification.
In our study we did not directly track the uptake of p5RHH-mRNA nanoparticles
into endosomes. However, the results we observed after inhibition of endosomal
acidification by bafilomycin are supported by previous studies using p5RHH-siRNA
nanoparticles that were colocalized with endosomal markers 241. Furthermore, we
observed that not all cells that were positive for the presence of the fluorescentlylabeled mRNA were also GFP positive. However, we interpreted the lack of increased
percentage of GFP expressing cells after chloroquine treatment to indicate efficient
endosomal escape, but this is not a direct measurement, which would require intensive
microscopic analysis. While we did not detect expression of GFP either by
immunoblotting or the presence of the synthetic mRNA by RT-PCR 48 hours after
administration of p5RHH-GFP nanoparticles to healthy mice, tissue distribution should
also be assessed at an earlier timepoint. In addition, the presence of the cargo mRNA
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could be determined in situ by utilizing the Cy5-labelled GFP mRNA, however, the
presence of the fluorescent signal would not necessarily indicate the expression of the
encoded protein. In fact, previous work with fluorescently-labeled p5RHH-siRNA
nanoparticles showed significant signal in the kidney after systemic administration but
no apparent effect of the treatment 245.

Overall Conclusions
In this study we investigated the influence of modified nucleotides on the
performance of miRNA switches. We found that incorporation of modified nucleotides
that significantly increase translation, such as Ψ and m1Ψ, tended to decrease the
miRNA-dependent regulation of miRNA switches. However, we also found that Ψ/m5C
modification enabled one miRNA target site at the 3’ UTR to regulate the miRNA switch
as effectively as four target sites. We also demonstrated that the effects of Ψ, Ψ/m5C,
and m1Ψ are dependent on the sequence of the miRNA site but not the proportion of
the number of modified nucleotides within the site. Furthermore, we found that effects of
nucleotide modification are modified miRNA switches with seed complementary target
sites are poorly regulated by miRNA, while placing the miRNA target site in the 5’ UTR
makes the miRNA-dependent silencing largely insensitive to nucleotide modification.
We also demonstrated that p5RHH peptides spontaneously form compact
nanoparticles in the presence of mRNA across a wide range of mRNA sizes. These
nanoparticles are highly transfective and RNase resistant. Furthermore, they achieve
robust endosomal escape with minimal cytotoxicity. Systemic delivery of p5RHH-mRNA
nanoparticles generated high expression levels of the synthetic mRNA exclusively in
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atherosclerotic plaque regions with no detectable expression in typical depot organs.
The simple method of production and the use of only biologically compatible solutions
makes p5RHH-mRNA nanoparticles an attractive platform for both pre-clinical and
clinical applications.
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Appendix A: USF IACUC Approval for Animal Studies
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Institutional Animal Care & Use Committee
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8/31/2017
Peptide-assisted mRNA delivery
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National Institutes of Health
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R IS00004197

PROTOCOL STATUS:
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The Institutional Animal Care and Use Committee (IACUC) reviewed your application requesting the use of
animals in research for the above-entitled study. The IACUC APPROVED your request to use the following
animals in your protocol for a one-year period beginning 8/31/2017:
Mouse: C57BL/6 ((20g male or female))
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Please take note of the following:
• IACUC approval is granted for a one-year period at the end of which, an annual renewal form must
be submitted for years two (2) and three (3) of the protocol through the eIACUC system. After three
years all continuing studies must be completely re-described in a new electronic application and submitted
to IACUC for review.
• All modifications to the IACUC-Approved Protocol must be approved by the IACUC prior to
initiating the modification. Modifications can be submitted to the IACUC for review and approval as an
Amendment or Procedural Change through the eIACUC system. These changes must be within the scope
of the original research hypothesis, involve the original species and justified in writing. Any change in the
IACUC-approved protocol that does not meet the latter definition is considered a major protocol change
and requires the submission of a new application.
• All costs invoiced to a grant account must be allocable to the purpose of the grant. Costs allocable
to one protocol may not be shifted to another in order to meet deficiencies caused by overruns, or for other
reasons convenience. Rotation of charges among protocols by month without establishing that the rotation
schedule credibly reflects the relative benefit to each protocol is unacceptable.
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